Investigation of quantitative and qualitative MtDNA alteration in breast cancer by Fan, Xiucheng
  1 
Investigation of Quantitative and Qualitative  
MtDNA Alteration in Breast Cancer 
 
 
 
 
Inauguraldissertation 
 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
 
von 
 
Xiucheng Fan 
aus Shenyang, China 
Basel, 2009 
  2 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von 
 
Prof. Michael N. Hall 
Prof. Raija LP Lindberg 
Prof. Xiao Yan Zhong, 
 
 
Basel, den 23 June 2009 
 
 
 
 Prof. Dr. Eberhard Parlow 
Dekan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  3 
Table of Content 
 
Abstract 
 
Acknowledgements 
 
Abbreviation 
 
Part I: Background of mtDNA ………………………………………………………………… 8 
1. General information of mtDNA ...………………………………………………………...9 
1.1 Mitochondrial structure and function ………………………………………………....9 
1.2 Mitochondrial genome …………………………………………………………….....14 
2. MtDNA and human cancer.……………………………………………………………....21 
2.1 MtDNA alteration in cancer..…………………………………………………………21 
2.2 MtDNA and carcinogenesis…………………………………………………………..25 
2.3 MtDNA and cancer diagnosis………………………………………………………...29 
2.4 MtDNA and cancer treatment………………………………………………………...31 
2.5 MtDNA and cancer prognosis………………………………………………………..35 
3. MtDNA in breast cancer………………………………………………………………….39 
3.1 Alterations of mtDNA in breast cancer………………………………………………39 
3.2 MtDNA as a potential biomarkers in breast cancer…………………………………..40 
 
Part II: Summary of Publications of Manuscripts……………………………………………45       
1. Study aim and experimental design……………………………………………………….46 
2. Summary of background…………………………………………………………………..47 
2.1 Instability of mtDNA…………………………………………………………………47  
2.2 MtDNA and human cancers………………………………………………………….48 
2.3 MtDNA and breast cancer…………………………………………………………....49 
3. Quantitative analysis of mtDNA…………………………………………………………..50  
3.1 Method setup for quantitative analysis……………………………………………….50 
3.2 MtDNA quantification in tissues of patients with breast cancer……………………..52 
3.3 MtDNA quantification in whole blood of patients with breast cancer……………….53 
3.4 MtDNA quantification in plasma of patients with breast cancer…….……………….55 
4. Qualitative analysis of mtDNA alteration…………………………………………………56 
4.1 Method setup for qualitative analysis………………………………………………...56 
4.2 Method validation with HPA study by sequencing…………………………………..59 
4.3 MtDNA mutations in tissues of patients with breast cancer………………………….61 
5. Correlation study…………………………………………………………………………..63 
5.1 Correlation study between quantitative & qualitative changes of mtDNA in tissues...63 
5.2 Correlation study between mtDNA changes in paired blood & in tissue samples…...64  
6. Prospect……………………………………………………………………………………66 
7. Publication and manuscript list……………………………………………………………67 
 
Part III:   References……………………………………………………………………………69 
 
Part IV:  Publications…………………………………………………………………………...83 
 
  4 
ABSTRACT 
 
Mitochondrial DNA (mtDNA) alterations including copy number variations and sequence 
variations are suspected to be associated with carcinogenesis. We established a multiplex 
quantitative real-time PCR to examine the quantities of mtDNA and nuclear DNA (nDNA) for 
analysing relative mtDNA content in blood and tissue samples of patients with breast cancer. We 
also developed a novel matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS) based MicroARRAY multiplex assay to identify mtDNA 
sequence variants at 22 nucleotide positions (np) in a single reaction.  
 
For the quantitative analysis, mtDNA content was significant decreased in cancerous breast 
tissues (51 cases) compared with the paired normal breast tissues (p = 0.000). The down-
regulation of mtDNA was observed in 82% of the cancerous samples. The similar down-
regulation has been also found in whole blood and plasma samples from patients with breast 
cancer. Using the MALDI-TOF MS, we analysed the 22 mtDNA mutations related to breast 
cancer in the 51 paired breast tissues (cancerous and normal).  154 mtDNA mutations were found 
in total, 49.35% in cancerous tissues and in 50.65% in paired normal samples.  Forty one tissue 
samples contain more than 2 mutations each. All these sequence variants were distributed at 5 np 
in a hotspot region around the displacement loop (D-loop). We investigated the relationship 
between the quantitative and qualitative mtDNA alterations in breast tissues, as well as the 
correlation between the alterations of mtDNA and some clinical/pathological parameters, such as 
patient age, tumour type, tumour size, lymph node involvement, extent of metastasis, stage, 
histological grading, and ER, PR, and HER-2/neu receptors in breast cancer. No associations 
were found between the quantitative and qualitative changes, as well as between the mtDNA 
changes and clinical/pathological parameters.  
 
Our data suggest that mtDNA alterations are indeed involved in breast cancer. Investigating 
mtDNA alterations in cancer might be helpful for developing biomarkers in the management of 
cancer patients. The methods used in this study for the investigation can be introduced as simple, 
accurate and cost-efficient tools.  
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1. General information of mtDNA 
1.1 Mitochondrial structure and function 
Mitochondria (singular mitochondrion, Fig 1) are membrane-bound organelles like the nucleus 
have a double membrane found in the cytoplasm of most eukaryotic cells. These organelles show 
the incredible diversity on both the size (0.5 to10 µm in diameter) and the copy number (1 to over 
1000) per cell. They are about the size of Escherichia coli with different shapes according to the 
cell types. However, the structures of mitochondria are pretty similar regardless of their size, 
number per cell, plant or animal origin. Generally, a mitochondrion has an inner membrane and 
an outer membrane as well. There is a space between the inner and outer membranes called the 
intermembrane space. The outer membrane is fairly smooth, whereas the inner membrane is 
greatly convoluted, forming folds or invaginations called cristae.  The cristae largely expand the 
inner membrane surface area. The space enclosed by the inner membrane is so called matrix. It 
contains a highly-concentrated mixture of hundreds of enzymes, mitochondrial ribosomes, tRNA, 
and several copies of the mitochondrial genome (Bruce et al. 2002). 
Mitochondria are involved in a series of cellular processes including cellular differentiation and 
proliferation, cell signaling, programmed cell death, the control of the cell cycle and cell growth 
(McBride et al. 2006). Besides these, mitochondria are so called cellular power plants for 
generating the most of the cellular chemical energy, adenosine triphosphate (ATP) for cell use 
(Campel et al. 2006). Mitochondria play the dominant role in oxidative phosphorylation 
(OXPHOS), combining the electron-transferring respiratory chain complexes I–IV and the ATP 
synthase (complex V).  
  11 
 
Figure 1. The strcture of mitochondrion (right part: electron micrograph).  
In the catabolism of carbohydrates, glucose is broken down into pyruvate from glycolysis in 
cytoplasm, and then pyruvate was transported from the cytoplasm into the mitochondria. The 
process of converting one molecule of glucose into two molecules of pyruvate generates 2 net 
nicotinamide adenine dinucleotides (NADH) finally. In mitochondrion one molecule of pyruvate 
undergoes the subsequent oxidation and decarboxylation to 2 molecule of acetyl coenzyme A by 
a cluster of three major protein complexes of pyruvate dehydrogenase, which is located in 
mitochondrial matrix. During the oxidative decarboxylation of pyruvate, one molecule of NADH 
is formed per pyruvate oxidized. Acetyl coenzyme A is oxidized through a cycle involving eight 
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catalytic steps, which is called citric acid cycle, and also known as the tricarboxylic acid cycle 
(TCA cycle), or the Krebs cycle.   
 
 
 
 
 
Figure 2. Metabolism in the matrix of mitochondria Pyruvate and fatty acids are imported from 
the cytosol and converted to acetyl CoA in the mitochondrial matrix. Acetyl CoA is then oxidized 
to CO2 via the citric acid cycle, the central pathway of oxidative metabolism (Cooper et al, 2000). 
 
 
Each round of the TCA cycle results in the production of two molecules of CO2, 3 molecules of 
NADH one molecule of reduced flavin adenine dinucleotide (FADH2), and one molecule of GTP 
(the energetic equivalent as ATP). In the next stage of the aerobic metabolism of oxidative 
phosphorylation, the respiratory substrates of NADH and FADH2 generated through the TCA 
cycle are oxidized in a process coupled to ATP synthesis. Substrate oxidation involved in a series 
of respiratory enzyme complex is located within the mitochondrial membrane and the ability to 
accept any free electrons in a particular sequence based on the relative redox potential and 
substrate specificity. Complex I (NADH coenzyme Q reductase) accepts electrons from the TCA 
cycle electron carrier NADH, and passes them to coenzyme Q (ubiquinone; CoQ), which also 
receives electrons from complex II (succinate - ubiquinone reductase).  Complex II consists of 
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four protein subunits; one is the FADH2-linked TCA cycle enzyme succinate dehydrogenase, 
transferring NADH from succinate to CoQ. CoQ passes electrons to complex III (Cytochrome c 
reductase/Cytochrome b complex), an 11 - subunits of respiratory enzyme complex involved in 
the transfer of electron from  membrane-bound CoQ to oxidised cytochrome C (Cyt C)within the 
outer surface of the mitochondrial membrane. Cyt C passes electrons to Complex IV. Complex 
IV (cytochrome C oxidase, COX) is the terminal mobile electron acceptor composed of 13 kinds 
of different protein subunits, which uses the electrons to reduce molecular oxygen to water. Three 
of the electron carriers (complexes I, III and IV) are proton pumps and function as the reception 
sites for the translocation of protons from the matrix side to the external side of the inner 
mitochondrial membrane. The resulting transmembrane proton gradient is used to make ATP via 
ATP synthase (complex V). Thus, each molecule of NADH leads to 3 molecule of ATP and each 
molecule of FADH2 leads to 2 molecules of ATP. Thereby each molecule of pyruvate enters the 
TCA cycle generating12 molecules of ATP. Totally one  
 
The ATP produced in the mitochondrion which is not utilized by mitochondrion need to exit to 
the cytosol via the enzyme adenine nucleotide translocase (ANT) for an exchange of cytosolic 
ADP. This exchange is the principal control for the rate of oxidative phosphorylation, which is 
the major supply of the cellular energy under aerobic conditions and is required to sustain cell 
viability and normal cell functions. 
 
 
Fatty acid oxidation is another important source of energy for many organisms, which metabolic 
catabolism also occurs in mitochondria. Fatty acid is catalyzed and transported from cytoplasm to 
inner mitochondrial space into fatty-CoA ready for beta oxidation machinery.  β-oxidation splits 
the long chain fatty acid into acetyl CoAs, which can enter the TCA cycle to generate NADH and 
FADH2. β-oxidation enzymes are separated to two functional groups, the inner membrane-bound 
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complex responsible for long-chain fatty acid oxidation and the soluble matrix responsible for the 
degradation of medium- and short-chain fatty acids (Liang et al. 2001), which carry on the 4-step 
repeat cycle. In each round of the cycle one molecule of acetyl CoA is decarboxylated to one 
acetyl-CoA and one acyl-CoA molecule with two carbon atoms shorten, which can re-enter the β 
-oxidation cycle until completely degraded to acetyl-CoA.  The resulting acetyl-CoA molecules 
enter the TCA cycle for further oxidation. However, under some certain physiological conditions 
for instance the long-term fasting and hungriness, or under some pathological conditions such as 
diabetes, the oxidation of fatty acids results into ketone bodies, β - hydroxybutyrate, acetoacetate 
and acetone, which is called ketogenesis catalyzed by the enzymes also located in the 
mitochondrial matrix. In these cases, the ketone bodies are used as an alternative energy source of 
energy in the skeletal muscles, heart and brain (Voet et al, 2006; McBride et al. 2006). 
 
In addition to oxidative metabolism, mitochondria are also involved in other metabolic tasks, for 
example, some enzymes functioning in gluconeogenesis (Sobll. 1995) and the urea cycle 
(Nakagawa et al. 2009) and are located in mitochondrial matrix. Mitochondria of the cells 
involved in regeneration of NAD, and steady-state in the cells of the inorganic ions such as 
calcium Calcium signaling (Hajnóczky et al, 2006), steroid synthesis (Rossier 2006). 
 
 
1.2 Mitochondrial Genome 
 
In addition to nuclear genomes, eukaryote cells also have cytoplasmic genomes which are 
compartmentalized in the mitochondria. Human mitochondrial DNA is extremely small molecule 
only about 16,569 base pairs (bp) in length located within the mitochondrial matrix and present in 
thousands of copies per cell., like most bacterial and prokaryote DNA, organized in a closed 
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circle like a donut, unlike human nuclear DNA, which is about 3.0 billion bp in length and is 
arranged in a long spiraled and coiled thread like structure and present only one pair of copy per 
cell. Unlike human nuclear DNA has 46 chromosomes (23 pairs) and about 30000 genes, human 
mitochondrial DNA genome only encodes 37 genes (Table 1). According to the nucleotide 
content, mitochondrial genome is differentiated into two strands. The guanine rich strand is 
referred to as the heavy strand and the cytosine rich strand is referred to as the light strand. The 
heavy strand encodes 28 genes, and the light strand encodes 9 genes for a total of 37 genes. The 
heavy strand encodes 12 of the 13 polypeptide-encoding genes, 14 of the 22 tRNA-encoding 
genes and both rRNA-encoding genes. Of the 37 genes, 13 are essential polypeptides of the 
OXPHOS system; 22 are for transfer RNA (tRNA) and two are for the small subunit and large 
subunit of ribosomal RNA (rRNA), which construct the necessary RNA machinery for their 
translation within the organelle (Fig. 3). The remaining protein subunits that make up the 
respiratory-chain complexes, together with those required for mtDNA maintenance, are nuclear-
encoded, synthesized on cytoplasmic ribosomes, and are specifically targeted and sorted to their 
correct location within the organelle. Therefore mitochondria are under the dual genetic control 
of both nuclear DNA and the mitochondrial genome (Taylor et al. 2005).  
 
Human mtDNA has no introns but extremely high proportion of contiguous coding sequences 
(Anderson et al. 1981, Wallace et al. 1992, Zeviani et al. 1998). The only non-coding segment of 
mtDNA is the displacement loop (D-loop), a region of 1121 bp that contains the origin of 
replication of the H-strand (OH) and the promoters for L and H-strand transcription. The mtDNA 
is replicated from two origins. DNA replication is initiated at OH using an RNA primer generated 
from the L-strand transcript. H-strand synthesis proceeds two-thirds of the way around the 
mtDNA, displacing the parental H-strand until it reaches the L-strand origin (OL), situated in a 
  16 
cluster of five tRNA genes. Once exposed on the displaced H-strand, OL folds a stem-loop 
structure and L-strand synthesis is initiated and proceeds back along the H-strand template. 
Consequently, mtDNA replication is bidirectional but asynchronous (Clayton 1982). MtDNA 
transcription is initiated from two promoters in the D-loop, PL and PH. Transcription from both 
promoters creates a polycistronic precursor RNA that is then processed to produce individual 
tRNA and mRNA molecules (Clayton et al. 1991, Ojala et al. 1981). To initiate transcription, the 
dedicated mitochondrial RNA polymerase (POLRMT) requires mitochondrial transcription factor 
A (TFAM,) and either mitochondrial transcription factor B1 (TFB1M) or B2 (TFB2M) 
(Falkenberg et al. 2002, Fernandez et al. 2003). Recent evidence shows that TFAM induces a 
structural change of the light-strand promoter that is required for POLRMT-dependent promoter 
recognition (Gaspari et al. 2004). The importance of mitochondrial transcription to cellular 
dysfunction as a result of pathogenic mtDNA mutations is a neglected area of research that might 
give important insights into some of the tissue-specific or mutation-specific effects. 
Furthermore, the genetic code in human mitochondria has come to differ from that used in the 
nucleus, and thus mtDNA genes are no longer intelligible to the nucleocytosolic system (Wallace 
1982). UGA is read as tryptophan rather than ‘stop’, AGA and AGG as ‘stop’ rather than 
arginine, AUA as methionine rather than isoleucine, and AUA or AUU is sometimes used as an 
initiation codon instead of AUG (Anderson et al. 1981, Montoya et al. 1981). 
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Figure 3. The human mitochondrial genome encodes 13 subunits of respiratory chain complexes: 
seven subunits (ND 1–6 and 4L) of complex I, cytochrome b (Cyt b) of complex III, the COX I–
III subunits of cytochrome oxidase or complex IV, and the ATPase 6 and 8 subunits of FOF1 ATP 
synthase. MtDNA also encodes 12S and 16S rRNA genes and 22 tRNA genes. The abbreviated 
amino acid names indicate the corresponding amino acid tRNA genes. The outer strand is heavy-
chain DNA and the inner one light-chain DNA. OH and OL are the replication origins of the light 
and heavy chain, respectively, while PH and PL indicate the transcription sites.  
(Modified from http://ipvgen.unipv.it/docs/projects/torroni_eng.html) 
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Product Category Symbol Gene Type nucleotide position 
12S RNA MT-RNR1 rRNA 648..1601 
16S RNA MT-RNR2 rRNA 1671..3229 
COX1 protein coding 5904..7445 
COX2 protein coding 7586..8269 Cytochrome C Oxidase (complex IV) COX3 protein coding 9207..9990 
ATP8 protein coding 8366..8572 ATP synthase 
(complex V) ATP6 protein coding 8527..9207 
ND1 protein coding 3307..4262 
ND2 protein coding 4470..5511 
ND4L protein coding 10470..10766 
ND5 protein coding 12337..14148 
ND4 protein coding 10760..12137 
ND6 protein coding 14149..14673 
NADH dehydrogenase 
(complex I) 
ND3 protein coding 10059..10404 
Coenzyme Q - cytochrome c reductase 
/Cytochrome b 
(complex III) 
CYTB protein coding 14747..15887 
No D-loop Non-coding 16024..16569; 1..576 
Phenylalanine MT-TF tRNA 577..647 
Valine MT-TV tRNA 1602..1670 
Leucine MT-TL1 tRNA 3230..3304 
MT-TL2 tRNA 12266..12336 Isoleucine MT-TI tRNA 4263..4331 
Glutamine MT-TQ tRNA 4329..4400 
Methionine MT-TM tRNA 4402..4469 
Tryptophan MT-TW tRNA 5512..5579 
Alanine MT-TA tRNA 5587..5655 
Asparagine MT-TN tRNA 5657..5729 
Cysteine MT-TC tRNA 5761..5826 
Tyrosine MT-TY tRNA 5826..5891 
MT-TS1 tRNA 7446..7514 Serine MT-TS2 tRNA 12207..12265 
Aspartic acid MT-TD tRNA 7518..7585 
Lysine MT-TK tRNA 8295..8364 
Glycine MT-TG tRNA 9991..10058 
Arginine MT-TR tRNA 10405..10469 
Histidine MT-TH tRNA 12138..12206 
Glutamic acid MT-TE tRNA 14674..14742 
Threonine MT-TT tRNA 15888..15953 
Proline MT-TP tRNA 15956..16023 
 
Table 1. MtDNA regions, encoding genes, and nucleotide positions. 
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Characteristic Nuclear genome Mitochondrial genome 
Size 
 
~3.3 x 109 bp 16,569 bp 
Number of DNA molecules 
per cell 
 
23 in haploid cells; 46 in 
diploid cells 
Several thousand copies per 
cell (polyploidy) 
Number of genes encoded ~20,000–30,000 37 (13 polypeptides, 22 tRNAs and 2 rRNAs) 
 
Gene density ~1 per 40,000 bp 1 per 450 bp 
Introns Frequently found in most genes Absent 
 
Percentage of coding DNA ~3% ~93% 
Codon usage The universal genetic code 
AUA codes for methionine; 
TGA codes for tryptophan; 
AGA and AGG specify stop 
codons 
Associated proteins 
Nucleosome-associated 
histone proteins and non-
histone proteins 
No histones; but associated 
with several proteins(for 
example, TFAM) that form 
nucleoids 
Mode of inheritance 
Mendelian inheritance for 
autosomes and the X 
chromosome; paternal 
inheritance for the Y 
chromosome 
Exclusively maternal 
Replication 
Strand-coupled mechanism 
that uses DNA polymerases α 
and δ 
Strand-coupled and strand-
displacement models; only 
uses DNA polymerase γ 
Transcription Most genes are transcribed individually 
All genes on both strands are 
transcribed as large 
polycistrons 
Recombination 
Each pair of homologues 
recombines during the 
prophase of meiosis 
There is evidence that 
recombination occurs at a 
cellular level but little 
evidence that it occurs at a 
population level 
 
 
Table 2. Comparision between the human nuclear and mitochondrial genomes. *Table modified 
from  (Taylor et al, 2005). TFAM, mitochondrial transcription factor A; rRNA, ribosomal RNA. 
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Except the difference at the codon usage, the copy numbers, mechanism of replication, the 
control of replication, mitochondrial genetics is also different from Mendelian genetics on its 
uniparental inheritance (Taylor et al, 2005) (Table 1). Human mtDNA is normally inherited 
exclusively from the mother, known as maternal inheritance. The mammalian egg contains 
100,000 to 1,000,000 mtDNA molecules, whereas a sperm contains only 100 to 1000 mtDNA 
molecules (Chen et al. 1995b, Manfredi et al. 1997). When the sperm fertilizes the egg, the sperm 
detaches the tail and except the nucleus of the sperm is used to fertilise, all the paternal 
mitochondria including mtDNA are lost early in embryogenesis, soon after fertilization, between 
the two-cell and four-cell stages. This could be due either to destruction of sperm mitochondria or 
to impaired replication of sperm mtDNA in the cells (Manfredi et al. 1997). However, this 
inheritance could be altered by cloned embryos or subsequent rejection of the paternal 
mitochondria. The paternal mtDNA was reported presenting at the blastocyst stage in some 
abnormal (polyploidy) human embryos produced by in vitro fertilization and intracytoplasmic 
sperm injection techniques (St John et al. 2000). A case study showed 2-bp pathogenic deletion 
in the mtDNA NADH dehydrogenase subunit-2 (ND2) gene in the muscle of a patient with 
mitochondrial myopathy was paternal in origin and accounted for 90 percent of the patient's 
muscle mtDNA (Schwartz et al. 2002). Although no any evidence of paternal transmission have 
been shown on the other patients with the same disease in the subsequent studies (Taylor et al. 
2003, Filosto et al. 2003, Schwarz 2004). 
Mitochondria are descendants of α-proteobacteria that formed an endosymbiotic relationship with 
ancestral eukaryotic organisms. In 1963 it was discovered that DNA was contained within the 
mitochondrion, and not only could they translate mRNA into protein, but also that the very genes 
for these proteins are present in the organelles. During its evolution into the present-day 
‘powerhouse’ of the eukaryotic cell the mitochondrion transferred many of its genes to the 
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nucleus. Whilst the mitochondrion is largely dependent on nuclear-encoded factors some 
functional independence remains. By definition, mitochondria in all organisms are able to carry 
out two functions: the expression of an integral genome and the generation of ATP coupled to 
electron transport (Futuyma 2005). 
In mitochondria, the cellular energy (ATP or the equivalent GTP) is produced through a process 
so called oxidative phosphorylation (OXPHOS), in which hydrogen is oxidized to generate water 
and ATP. MtDNA is located in the mitochondrial matrix close to the internal mitochondrial 
membrane. Due to the close proximity to ATP production site, mtDNA is highly exposed to 
strongly mutagenic reactive oxygen species (ROS) generated as by-products of OXPHOS. 
Moreover mitochondria seem to lack protective proteins such as histones and lack an efficient 
DNA repair system (Richter et al. 1988, Bogenhagen et al. 1999). Therefore mtDNA is 
vulnerable to oxidative damage and accumulate sequence mutations. Furthermore, it seems 
deviant mitochondrial metabolism might accelerate the rate of mtDNA mutation (Lightowlers et 
al. 1997). These unique features probably cause the mutation rate of mtDNA is 10 times higher 
than that in nuclear DNA (Cavalli et al. 1998). 
Sometimes mutations arising in mtDNA generate an intracellular mixture with both mutant and 
normal mtDNAs, which is termed as heteroplasmy. If only the wild-type or all mutant mtDNA is 
found in cells, which condition is described as homoplasmy. During the cell division, the 
mitochondria and their genomes undergo a process so called replicative segregation, in which 
mitochondrial genomes random replicate and partition into daughter cells. Hence only a small 
number of mtDNA molecules in the mother are passed on to the next generation, which results to 
the mitochondrial genetic bottleneck. It could also explain that although a high copy number of 
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mtDNA present in mature oocytes versus a relatively small number of cell divisions in the female 
germline, mtDNA sequences could variate remarkably between generations (Poulton et al. 1998). 
2 MtDNA and human cancer 
 
 
2.1 MtDNA changes 
 
 
To date, various types of mtDNA alterations including point mutations, instability of mono- or 
dinucleotide repeats, mono- or dinucleotide insertions, deletions, or quantitative alterations have 
been identified virtually in solid tumors, such as colon, stomach, live, kidney, bladder, prostate, 
skin and lung cancer (Chatterjee et al, 2006; Brandon et al. 2006), and hematologic malignancies, 
such as leukaemia and lymphoma (Fontenay et al. 2006).  
 
In a study, by the entire mitochondrial genome sequencing analysis of human colorectal cancer 
cell lines, 70% (7/10) were found to carry mutations in protein coding genes or rRNA qenes, 
which also revealed that most of the mtDNA mutations were homoplasmic (Polyak et al. 1998). It 
has been reported that 64% (9/14) of bladder cancers, 46% (6/13) of head and neck cancers, and 
43% (6/14) of lung cancers harboring point mutations of mtDNA. It was as well addressed that 
the majority of these somatic mutations of mtDNA were homoplasmic (Fliss et al. 2000). Other 
than point mutations, a 40 bp insertion within the COX I gene has been reported to be associated 
with renal cell oncocytoma (Welter et al. 1989), while it has been found a deletion happened to 
NADH dehydrogenase subunit III, which lead to the loss of mtDNA, is specifically linked to 
renal carcinoma (Selvanayagam et al. 1996). Two types of frame-shift mutations of 3571_3572 
ins C and 11038 del A have also been detected in thyroid oncocytomas as well as in renal 
oncocytoma tissues (Mayr et al. 2008). It has been reported that the frequency of missense 
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mutations on COX I in prostate cancer patients was significantly higher compared to the non-
cancer controls in a population based study (Petros et al. 2005). 
 
In addition to mutations in the coding region of mtDNA, a high frequency of somatic mutation 
was located in the non-coding displacement loop (D-loop) region of mtDNA. The D-loop region 
has been described as the most frequent host for mtDNA mutations in variety of human cancers. 
Several studies of somatic mutation in the D-loop region of mtDNA has revealed that insertions 
or deletions at nucleotide position (np) 303-309, a polycytidine stretch (C-tract) termed D310, are 
the most common mutations of mtDNA in human cancers including colorectal cancer (Lievre et 
al. 2005), gastric cancer (Wu et al. 2005), hepatocellular carcinoma (Tamori et al. 2004), 
melanoma (Takeuchi et al. 2004), ovarian cancer (Liu et al. 2001), uterine serous carcinoma 
(Pejovic et al. 2004). The D-loop is a triple stranded non-coding region with regulatory elements 
required for replication and transcription of the mtDNA. Hence mtDNA mutations in this region 
might responsible for the changes on copy number and gene expression of the mitochondrial 
genome.  
 
Based on the published data, Carew and his colleagues addressed four common features of 
mtDNA mutations in all tumor types including that the base substitutions are the most common 
mutations; mutations occur in all protein coding mitochondrial genes; the D-loop region is the hot 
spot of somatic mutations among most of tumor types; and the presence of homoplasmic mutant 
mtDNA in tumors suggests that they may play an important role in the development of tumors 
(Carew et al.2002).  
Large-scale deletions of mtDNA have been detected in various types of cancers (Carew et al. 
2002). For example, it was reported that a 4,977 bp deletion was largely accumulated in sun-
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exposed skin tissues, the squamous cell carcinomas and precancerous skin tissues (Pang et al. 
1994). The 4,977 bp deletion of mtDNA was later detected in oral cancers and paired non-
malignant oral tissues of patients with betel quid chewing history (Lee et al. 2001). Moreover, an 
increase of mtDNA large-scale deletions was reported in radiation-associated thyroid tumors 
(Rogounovitch et al. 2002). However, even the 4,977 bp deletion of mtDNA has been frequently 
detected in various types of cancers; the incidence and amount of the 4,977 bp-deleted mtDNA 
are significantly lower in the malignant tissues as compared with the paired normal tissues of 
cancer patients. It has been suggested that during cancer progression the mtDNA with a deletion 
is decreased (diluted) as a result of clonal expansion of cell lineages that contain less or no 
mtDNA deletion. The study with micro-dissected tumor tissues further confirmed the lower 
incidence of 4977 bp mtDNA deletion in most tumors (Dani et al. 2004). 
 
Alterations in the copy number have also been found in human cancers. The copy number of 
mtDNA was found to be increased in papillary thyroid carcinomas (Mambo et al 2005) and 
during endometrial cancer development (Wang et al. 2005). While the elevated mtDNA content 
has been detected in saliva from patients with primary head and neck squamous cell carcinoma, 
which was significantly higher than that of controls, and it was found that the increase of mtDNA 
content was associated with advanced tumor stage (Jiang et al. 2005). In addition, it was observed 
in head and neck cancers that mtDNA content was increased with histopathologic grade from 
normal, moderate, dysplasia, severe dysplasia to invasive tumors, which demonstrated the rising 
incidence with histopathologic grade (Kim et al. 2004). The increase in mtDNA content was 
thought to be a feedback mechanism that compensates for a decline in respiratory function.  
 
In contrast, it has been reported that the copy numbers of mtDNA were frequently reduced in 
hepatocellular carcinomas (HCCs). And, this reduction of mtDNA copy number of was more 
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frequently observed in female patients with HCCs as compared with male patients with HCCs. 
This finding suggests that the differential alterations in the mtDNA copy number of cancer 
tissues of male and female patients may contribute to the differences in clinical manifestation, 
progression, and mortality rate between male and female HCC patients (Yin et al. 2004). It has 
also been reported that mtDNA content was reduced in HCCs compared with the corresponding 
non-cancerous liver tissues, and that low mtDNA content of HCCs was significantly correlated 
with large tumor size and liver cirrhosis (Yamada et al. 2006). In gastric cancers, the association 
between the clinicopathological features and the mtDNA content has been addressed and it was 
found that a decrease of mtDNA content is significantly associated with ulcerated and infiltrating 
type (Borrmann’s type III) and diffusely thick type (Borrmann’s type IV) of gastric carcinomas 
(Wu et al. 2004). These findings suggest that a decrease in the mtDNA content is associated with 
the progression of ovarian cancer.  
 
However, both increases and decreases in mtDNA content in contrast to non-malignant controls 
were observed in each cancer type in a comprehensive investigating on mtDNA copy number in 
study with 54 hepatocellular carcinomas (HCCs), 31 gastric, 31 lung, and 25 colorectal cancers 
(Lee et al. 2005). The mtDNA content in ovarian carcinomas was found to be significantly higher 
than that in normal ovaries (Wang et al. 2006). Whereas, it was shown that the mtDNA content in 
the pathologically high-grade (poorly differentiated) ovarian cancer was lower than that of the 
low-grade (well differentiated) ovarian cancer (Wang et al. 2006). Recently, a study of 153 
colorectal cancer patients revealed that mtDNA content in colorectal cancers was higher than that 
in the corresponding non-cancerous colon tissues. However, the mtDNA content was decreased 
in colorectal cancers with higher TNM stages and poorer differentiation (Lin et al. 2008).  
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These findings suggest that a change in the content of mtDNA might not be associated with a 
certain type of cancers, and the actual copy number of mtDNA in certain cancers might depend 
upon the specific sites of mtDNA mutations attached to that cancer. On one hand, it was suggest 
that somatic mutations in the D-loop of mtDNA and impairment in mitochondrial biogenesis may 
contribute to the decrease of mtDNA copy number in human cancers (Lee et al. 2005). On the 
other hand, mtDNA mutations located within genes encoding oxidative phosphorylation proteins 
might be expected to result in an increase in mtDNA copy number. It has been hypothesized that 
this might occur as a compensatory response to the decline in respiratory chain function (Kim et 
al. 2004).  
 
2.2 MtDNA and Carcinogenesis 
 
 
Uncontrolled cell growth and altered energy metabolism are two essential properties of tumour. 
Mitochondria play a fundamental important role in energy metabolism, and programmed cell 
death, suggesting mitochondria might serve as the key switch for carcinogenesis (Cavalli et al. 
1998). In 1920s Otto Warburg observed in tumour cells the most cellular energy was produced by 
glycolysis even under aerobic condition, which is termed as aerobic glycolysis. Since aerobic 
glycolysis is in contrast to 'Pasteur effect' in normal cells, Warburg hypothesized cancer was 
caused by the irrversible injury to the mitochondrial respiratory machinery (Warburg et al . 1924, 
Warburg 1956).  
 
Warburg’s observation extremely inspired investigation on mitochondrial function in tumors. In 
1998 it was reported by Vogelstein and colleagues that mtDNA mutations were present in 7 out 
of 10 colorectal cancer cell lines in their landmark study (Polyak et al. 1998). This is the first 
paper to describe the presence of somatic mtDNA mutations in solid human tumours, in this case 
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colon cancer. In many cases, the mtDNA mutations had accumulated to homoplasmic levels and 
were not evident in the matched normal tissue from the same patient. A causal relationship 
between mtDNA mutations and tumorigenesis is yet to be established. Since then, the presence of 
somatic mtDNA mutations has been reported in both solid tumours and leukaemias (Robert et al. 
2005). It was suggested that the high rates of mtDNA mutations observed in cancer cells may 
lead to mitochondrial dysfunction and reduce the cellular ability to generate ATP through 
OXPHOS (Carew et al. 2002; Singh 2004; Brandon et al. 2006). Moreover, malfunction of 
mitochondrial respiratory chain could also enhance electron leakage, leading to increased ROS 
production. This speculation led Carew and colleagues to use primary human leukemia cells 
isolated from patients to examine mtDNA mutations and their correlation with alteration in 
cellular ROS and mitochondrial mass. It was found that mtDNA mutations in leukemia cells were 
closely associated with increased ROS (Carew et al. 2004). 
 
ROS are well known for its damage effect and take a role in decreasing mitochondrial ATP 
production, as well as in both the initiation and promotion of tomor (Shigenaga et al. 1994; Gille 
et. al 1992; Zhang et al. 1990). It has been shown HeLA cells with DNA-depleted mitochondria 
generate high levels of ROS, in part due to electron leakage generated by the presence of nuclear 
DNA-encoded Complex II system and ubiquinone (Miranda et al. 1999). A research group 
reported that mutants completely devoid of mtDNA in yeast show 3 to 6 fold increases in 
spontaneous nuclear mutation rates (Flury et al. 1976). Model systems expressing altered levels 
of adenine nucleotide translocators, Mn-superoxide dismutase, ubiquinone or nitric oxide 
synthase could be used to study the predicted association between mitochondrial ROS production 
and nuclear mutation frequency. Recent data indicate that Mn-SOD knockout mice show 
increased oxidative DNA damage (Melov et al. 1999). Oxidative damage induced by ROS is 
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probably a major source of mitochondrial genomic instability leading to respiratory dysfunction 
resulting in cancer growth. 
Fragments of mtDNA are sometimes found in nuclear genes, for example, sequences representing 
subunits ND4 (Complex I) and subunits cytochrome c oxidases I, II and III (Complex IV) are 
present in the nuclear DNA of various tissues (Corral et al. 1989). And the insertion of mtDNA in 
nuclear genes has been suggested as a mechanism by which oncogenes are activated (Corral et al. 
1989; Reid et al. 1983). 
 
Recently some studies suggest the functional significance of mtDNA mutations and depletions in 
tumorigenesis and/or tumor progression.  It has been reported some somatic mtDNA mutations 
and mtDNA depletion in gastric cancer might be involved in carcinogenesis of breast and gastric 
carcinoma (Boddapati et al. 2005), while it has been shown mtDNA mutations also appear to play 
a role in development digestive tract cancer (Kose et al. 2005). Shidara and colleagues have 
shown that specific point mutations in mtDNA accelerated tumor growth and reduced apoptosis 
(Shidara et al. 2005). These point mutations are in the mitochondrial ATP synthase subunit 6 
gene (MTATP6) and are associated with maternally inherited Leigh syndrome but have also been 
detected in a variety of tumors (Maximo et al. 2002, Yeh et al. 2000, Tan et al. 2002). These data 
support the notion that point mutations occurring in tumors within mtDNA can have functional 
advantages as they promote tumor growth. In another comprehensively study of 25 colorectal 
cancers, 31 gastric cancers, 54 hepatocellular carcinomas and 31 lung  cancers , it has been 
reported the incidence of somatic D-loop mutations is higher in   later stage cancers than that of 
early stage cancers (Lee et al. 2005). These findings suggest that instability in the D-loop region 
of mtDNA may be involved in carcinogenesis of human cancers.  
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In prostate cancer both germline and somatic mtDNA COI missense and nonsense mutations 
have been found to be associated with prostate cancer. Moreover, when the mtDNAs of a prostate 
cancer cell (PC3) were substitution with a patient mtDNA harboring the pathogenic np T8993G 
ATP6 mutation the resulting PC3 (mtDNA T8993G) cell lines generated much more rapidly 
growing tumors in nude mice than did the PC3 prostate cancer cell lines in which the resident 
mtDNA was replaced with a mtDNA from the same heteroplasmic patient but harboring the 
normal base, PC3 (mtDNA T8993T). This increased tumorigenicity was associated with 
increased ROS production, indicating that mtDNA mutations that increase ROS production may 
bean important factor in tumorigenicity (Petros et al., 2005). 
 
It has also been suggested by the trans-mitochondrial hybrid (cybrid) studies that mtDNA plays 
an important role in establishing and/or maintaining the tumorigenic phenotype. For example, the 
evidence of increased tumorigenic phenotype had been shown in a rho0 derivative of human 
osteosarcoma cells, which showed increased anchorage independent growth compared to the 
parental cells. In turn, the parental phenotype was restored by transfer of wild type mitochondrial 
DNA to rho0 cells displaying reduced anchorage independent growth (Singh et al. 2005). These 
studies suggest that inter-genomic cross talk between mitochondria and the nucleus plays an 
important role in tumorigenesis and that retrograde signaling from mitochondria to nucleus may 
be an important factor in restoration of the non-tumorigenic phenotype. In the further studies by 
Singh’s group it is found that retrograde mitochondria-to-nucleus signaling has important role in 
regulation of NADPH oxidase (Nox1), and that over-expression of Nox1 in most of breast and 
ovarian tumors (Desouki et al. 2005). The cluster of Nox enzymes consist of seven structurally 
related homologues, Nox 1-5 and dual oxidase 1 and 2 (Desouki et al. 2005; Lambeth et al). 
2004), and Nox 1 encoded by nuclear DNA is a major source of endogenous ROS in the cell 
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(Desouki et al. 2005). With the same technique the functional significance of mtDNA mutations 
is demonstrated in another studys. Cybrids harboring the ATP6 T8993G mtDNA mutation in 
prostate cancer (PC3) cells were found to generate tumors that were 7 times larger than wild type 
cybrids, which barely grew in mice (Petros et al. 2005).  In addition, cybrids constructed using a 
common HeLa nucleus and mitochondria containing a point mutation at nucleotide position 8993 
or 9176 in ATPsynthase subunit 6 were present a growth advantage in early tumor stages after 
transplantation into nude mice. This growth advantage might possibly occur via prevention of 
apoptosis (Shidara et al. 2005). These studies indicate that mtDNA mutations might directly 
promote tumor growth in vivo. 
 
Moreover, it is also reported that mitochondrial dysfunction leads to chromosomal instability 
(CIN), a hallmark of cancer cells, present in a variety of primary human tumors, which suggests 
mitochondria-led nuclear mutations may be a causative factor in tumorigenesis. In addition, the 
redox factor 1 (Ref1, also known as Ape1 and Hap1) was found to plays a key role in genomic 
instability. Ref1 expression was altered in a variety of tumors. Together, these studies suggest 
that mitochondria-to-nucleus retrograde redox regulation due to mitochondrial dysfunction may 
also contribute to tumorigenesis (Singh et al. 2005)  
 
2.3  MtDNA and cancer diagnosis 
 
In the last twenty years various approaches have been developed and investigated on detecting 
specific molecular markers in clinical samples to improve the outcomes of conventional cancer 
screening (Sidransky, 2002). Though the changes of nuclear genetic and epigenetic have been 
regarded as the cornerstone of such studies, mitochondrial cellular content and mutations are also 
emerging as new molecular markers for clinical application. The feature of sheer abundance and 
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homoplasmic tendency make mtDNA an attractive biomarker for cancer (Sing et al. 1998 and 
1999, Polyak et al. 1998). In patients with lung cancer, bronchoalveolar lavage samples were 
found to harbour almost 200-fold more mitochondrial mutations than nuclear TP53 (Fliss et al. 
2000). In addition to bronchoalveolar lavage samples in lung cancer, mtDNA mutations have 
been readily detected in urine and blood from patients with bladder and head and neck cancers 
(Fliss et al. 2000); serum of hepatocellular carcinoma patients (Okochi et al. 2002); nipple 
aspirate fluid from patients with breast cancer (Zhu et al. 2005). Mitochondrial DNA can serve as 
a reliable and sensitive biomarker of cumulative UV radiation exposure in skin (Harbottle et al. 
2006). MtDNA mutations within the D-loop control region have been used as clonal markers in 
hepatocellular carcinoma (Nomoto et al. 2002) and breast cancer (Parrella et al. 2001). Moreover, 
mtDNA sequence variants have been detected with a rapid and high throughput sequencing 
method in patient tumor tissue and blood samples (Jakupciak et al. 2005).  
 
However, the mitochondrial genome is highly variable and the ease of whole-genome sequencing 
does not resolve some diagnostic dilemmas because the interpretation of a novel sequence change 
can be difficult in relation to potential pathogenicity (McFarland et al. 2004). It has been also 
mentioned that direct sequencing of tumor mtDNA, common performed in many studies, is a 
poor screening technique, since it misses levels of heteroplasmy below approximately 20%; 
whereas a better method is denaturing high-performance liquid chromatography followed by 
confirmatory polymerase chain reaction/restriction fragment length polymorphism analysis 
(Zanssen et al, 2005).  
In despite of extensive study reports on the identification of mitochondrial DNA mutations in a 
wide range of human cancers, the exact role of mitochondrial DNA mutations in tumor 
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development and progression has not been established. Thus, new technologies need to be further 
investigated to detect mitochondrial genetic and somatic alterations so as to provide an 
opportunity for large-scale analysis of mitochondrial mutations in human cancers. Therefore the 
link of functional mtDNA alteration to cancers could be applied on routine clinical diagnosis 
including screening. 
 
The alterations of mtDNA including mutations, insertions, deletions and instability are emerging 
as new biomarkers for detecting many cancers in tissue samples and body fluids which can be 
probably implemented in population screening trials (Verma et al, 2007). By using MitoChip for 
rapid sequencing of the entire mitochondrial genome, somatic mtDNA alterations were observed 
in preneoplastic lesions of the gastrointestinal tract, even in the absence of histopathological 
evidence of dysplasia (Sui et al. 2006). Undoubtedly single clinical application with MitoChip 
could be to augment diagnosis, but by the validation of mtDNA detection in body fluids 
harbouring shed tumor derivatives this application could be significantly advanced (Folkman 
2001). The development of the high-throughput mtDNA resequencing microarray is a milestone 
in mutation and polymorphism detection techniques, which is applicable to improve cancer 
diagnosis. These findings support the rationale for exploring the mitochondrial genome as a 
biomarker for the early diagnosis of cancer. 
 
2.4 MtDNA and cancer treatment 
 
 
MtDNA not only represents a signature of personal identity, but also serves as a log book 
accumulating mutations unique to each person. Thus, the mitochondrial genomic information has 
already impacted genetic counselling procedures and provided insights into novel avenues for 
treatment (Jakupciak et. 2006). Since mitochondria play a critical role of in apoptosis, it is 
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conceivable that mutations in mtDNA in cancer cells could significantly affect the cellular 
apoptotic response to anticancer agents. Experiments with rho0 cells without mtDNA evaluate the 
role of respiration in drug sensitivity resulting in various results, which might reflect complex 
interactions between rho0 cells and anticancer agents with disparate function mechanisms. To 
evaluate the changes in drug sensitivity in cancer cells bearing mtDNA mutations could be even 
more complicated, since different types of mtDNA mutations are likely to have diverse effects on 
the apoptotic response. Nevertheless, the clonal selection/expansion hypothesis could predict that 
the mutations recovered from cancer cells which survive chemotherapy are likely to be associated 
with resistance to the particular anticancer drugs being used in previous therapy. Furthermore, 
some particular mtDNA mutants in cancer cells are likely to arouse the respiratory chain 
dysfunctions and increase ROS generation. This biochemical change offers a unique opportunity 
to selectively kill this population of cancer cells by using agents that inhibit free radical 
elimination and cause further ROS accumulation, leading to lethal damage in the cancer cells 
(Huang et al. 2000). Taken together, it is evident that mtDNA mutations are clinically relevant 
and have potential therapeutic implications.  
 
The cancer cells with defective mitochondria and mtDNA mutants also produce larger amounts 
of ROS and are thus exposed to higher oxidative stress. The mitochondria with higher oxidative 
stress might utilize the retrograde signaling pathways to modulate the expression of nuclear genes 
involved in glycolysis and mitochondrial respiration and OXPHOS. This phenomenon, so called 
Warburg effect, might explain the observed increase in glucose utilization and higher lactate 
production in the formation and progression of cancers (Lee et al). The distinct differences in 
mtDNA structure and function between cancer cells and normal cells provide the potential for 
clinical use of mitochondria and mtDNA as targets for novel and site-specific anticancer agents 
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(Weissig et al. 2001, Modica-Napolitano et al. 2002). Therefore, development of drugs that target 
to mitochondria or mtDNA may improve treatment of some types of human cancers in the future. 
 
One chemotherapeutic strategy it to employ delocalized lipophilic cations (DLCs) which 
selectively accumulate in carcinoma cells in response to elevated mitochondrial membrane 
potential. Several of these compounds have exhibited some degree of efficacy in carcinoma cell 
killing in vitro and in vivo (Sun et al. 1994, Koya et al. 1996, Weisberg et al. 1996). Efforts have 
also been made to enhance the selective tumor cell killing of DLCs by combination with other 
anti-cancer agents, including AZT (Modica-Napolitano et al. 2004).  Some DLCs have been 
applied in photochemotherapy (PCT), an investigational cancer treatment involving light 
activation of a photoreactive drug, or photosensitizer, that is selectively taken up or retained by 
malignant cells (Modica-Napolitano et al. 2003, Lo et al. 2005). It has been considerably 
interested in PCT as a form of treatment for neoplasms of the brain, breast, bladder, lung, skin or 
any other tissue accessible to light transmitted either through the body surface or internally via 
fiber optic endoscopes. Cationic photosensitizers are particularly promising as potential PCT 
agents. Similar as other DLCs, these compounds are converged by cells into mitochondria in 
response to transmembrane potentials, and are thus particularly accumulated in the mitochondria 
of carcinoma cells. The photosensitizer can be converted to a more reactive and highly toxic 
species in response to localized photoirradiation, so as to strengthen the selective toxicity to 
carcinoma cells and offer a means of highly specific tumor cell killing without injury to normal 
cells (Chatterjee et al. 2008).  
 
One alternative strategy is to employ mitochondrial membrane protein-import machinery to 
deliver macromolecules into mitochondria. Using the similar machinery, a mitochondrial signal 
sequence has been used to direct green fluorescent protein to mitochondria, which promises the 
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visualization of mitochondria within living cells (Rube et al. 2004). Some peptides containing 
two functional domains, one homing motif for targeting particular cell types and the other pro-
apoptotic sequence, readily infiltrate via the mitochondrial membrane and turn into toxic when 
internalized into the targeted cells by disruping mitochondrial membranes (Modica-Napolitano et 
al. 2004). Another chemotherapeutic strategy is to target specific mitochondrial membrane 
proteins to alter membrane permeabilization and ultimately induce apoptosis (Cullen et al. 2007).  
Attempts have been made also to develop mitochondriotropic drug and mtDNA delivery systems. 
One study demonstrates that conventional liposomes can be conferedd mitochondria-specific by 
attaching to the known mitochondriotropic residues to the liposomal surface (Liguori et al. 2008)  
 
Furthermore, DQAsomes made from derivatives of the self-assembling mitochondriotropic bola-
amphiphile dequalinium chloride, have been exhibited the capacity to bind and transport 
oligonucleotides as well as plasmid DNA conjugated to a mitochondrial leader sequence (MLS) 
to mitochondria in living mammalian cells and release DNA on contact with mitochondrial 
membranes (Dsouza et al. 2005). The long-term therapeutic goal of this type of research is to 
produce mitochondria-specific vehicles which could effectively deliver drugs or mtDNA into the 
organelle to destroy malfunctioned mitochondria or restore mitochondria with healthy copies of 
the genome. 
 
Due to the important role of mitochondria in ATP metabolism, in generation of free radicals, and 
in regulation of apoptosis, it has been indicated mtDNA mutations are likely to affect cellular 
energy capacities, increase oxidative stress, cause ROS-mediated damage to DNA, and alter the 
cellular response to apoptosis induction by anticancer agents (Penta et al. 2001, Copeland et al. 
2001). However, apoptosis was found to occur less frequently in the mutant cybrids in cultures as 
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compared with wild-type cybrids, which suggests that the pathogenic mtDNA mutations might 
promote the growth of tumors by preventing apoptosis (Shidara et al. 2005). The mutant mtDNA 
in cybrids also exhibited resistance to cisplatin-induced apoptosis (Shidara et al. 2005). These 
results suggest that pathogenic mtDNA mutations might contribute to the progression of cancers 
and tolerance against anticancer drugs. The presence of somatic D-loop mutations might be a 
factor of resistance to fluorouracil based adjuvant chemotherapy in stage III cancers (Lievre et al. 
2005). It has been also found that mtDNA mutations in leukemia cells were closely associated 
with altered sensitivity to drug treatment (Carew et al. 2003). Moreover, mtDNA has also been 
shown to determine the hormone dependence in breast cancer cell lines. Naito and colleagues 
stablished hydroxytamoxifen-resistant breast cancer cells by growing human breast cancer cells 
MCF-7 in the presence of hydroxytamoxifen. They found that the mtDNA content was 
significantly reduced in the hydroxytamoxifen-resistant breast cancer cells. They further 
demonstrated that depletion of mtDNA induced by hormone therapy or other independent insults 
could trigger a shift to acquired resistance to hormone therapy in breast cancers (Naito et al. 
2008).  
 
 
2.5 MtDNA and cancer prognosis 
 
 
Numerous biomarkers have been evaluated to predict morbidity and mortality in patients with 
cancer, although few have proved entirely useful. In a small scale study with 19 cases of cervical 
cancer, mtDNA D-loop mutations are found to be possibly caused by HPV infection, and are not 
associated with the histopathological grade and tumor staging (Sharma et al. 2005). Similarly a 
rarely mtDNA D-loop 16519 somatic mutations found in pancreatic cancer, which cannot be 
considered causative events for this tumor type and probably are epiphenomena, but probably 
worsens pancreatic cancer prognosis (Navaglia et al. 2006). In a mutation analysis of eight 
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sample pairs of papillary thyroid carcinomas and six of follicular thyroid carcinomas tissue with 
the corresponding normal thyroid tissue, it has not been found mtDNA mutations to be correlated 
with statistically validated clinical prognosticators for recurrence or survival (Witte et al. 2007). 
A study of 109 patients with head and neck cancers revealed that the presence of D-loop 
mutations of mtDNA was not associated with the prognosis or the response of patients to 
neoadjuvant chemotherapy (Lièvre et al. 2006). Moreover, no significant association was found 
between somatic mtDNA mutations and clinicopathological characteristics in esophageal cancer 
(Hibi et al. 2001), gastric cancer(Wu et al. 2005), lung cancer (Jin et al. 2007), and ovarian cancer 
(Bragoszewski et al. 2008) respectively. 
 
However, in other studies mtDNA exhibits the potential to be a molecular biomarker to monitor 
cancer prognosis. In a 10 years retrospective study on 41 patients with invasive carcinoma of the 
uterine cervix, the results suggest that multiple mtDNA mutations are an independent marker of 
poor prognosis (Allalunis-Turner et al. 2006). It has been suggested by a study with analysis on 
somatic mutations in the D-loop region, the common 4,977-bp deletion, and the copy number of 
mtDNA in breast cancer and paired nontumorous breast tissues from 60 patients that somatic 
mtDNA mutations in D-loop region could be used as a molecular prognostic biomarker in breast 
cancer (Tseng et al. 2006). It has been also report in a study with 59 cases of invasive breast 
tumors and paired non-tumorous tissues indicated that patients with reduced mtDNA content had 
significantly poorer disease-free survival and overall survival rate, which suggested that reduced 
copy number of mtDNA may be involved in breast neoplastic transformation or progression and 
mtDNA content might be potentially used as a tool to predict prognosis (Man et al, 2007).  
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Moreover, it has also been found in 202 patients with non-small cell lung cancer, the average 
mutation rate in the D-loop of mtDNA of patients at stage IIIB or stage IV was significantly 
higher than that of patients at lower clinical stages. And the stage IIIB or stage IV cancer patients 
carrying point mutations in the D-loop of mtDNA exhibited poorer prognosis compared with 
those free of the mtDNA mutations (Matsuyama et al. 2003).  
Additionally, a population-based study on 365 patients with colorectal cancer recorded with 3 
years follow-up, the presence of tumor D-loop mutation appears to be a factor of poor prognosis 
in colorectal patients (Lievre et al. 2005). Another study of 153 colorectal cancer patients 
revealed that mtDNA content in colorectal cancers was higher than that in the corresponding non-
cancerous colon tissues. Whereas the mtDNA content decreased in colorectal cancers was 
associated with higher TNM stages and poorer differentiation. The decrease in mtDNA content 
was correlated with a lower expression level of mitochondrial transcription factor A (mtTFA) or 
β subunit of the mitochondrial ATP synthase (β-F1-ATPase). It was suggested that mitochondrial 
dysfunction is associated with poor prognosis of colorectal cancer (Lin et al. 2008). It has been 
reported that patients with lower mtDNA content in HCCs tended to show poorer 5-year survival 
compared with the patients with higher mtDNA content in HCCs, which suggest that decrease in 
the mtDNA content may be associated with malignancy of HCCs (Yamada et al. 2006). 
Similarly, most patients with types III and IV gastric cancers, respectively, were found to have 
poor prognosis and lower 5-year survival rate after gastric resection. These results suggest that 
the reduction in the content of mtDNA may contribute to the malignancy and progression of 
gastric cancers (Wu et al. 2004). 
 
The correlations between clinicopathological parameters and somatic mtDNA alterations in 
certain cancers indicate mtDNA alterations might potentially be used as a molecular prognostic 
  39 
indicator of cancers. Their correlations with poorer prognosis suggest that somatic mtDNA 
alterations in cancers may contribute to tumor recurrence and drug resistance in the process of 
cancer progression. In contrast, these correlations are absent in other cancers such as esophageal 
cancer, head and neck cancer, which suggest the function of mtDNA alteration might be site or 
tissue specific.   
 
 
3. MtDNA in breast cancer 
 
 
3.1 Alterations of mtDNA in breast cancer 
 
Several studies have examined the presence of mtDNA mutations in breast cancer. In one of the 
most comprehensive studies 19 sets of paired normal and tumor tissues from the same patients 
with breast cancer has been analyzed by using a combination of temporal temperature gel 
electrophoresis and direct DNA sequencing of the complete mitochondrial genome. Somatic 
mutations were identified in 74% of patients. The bulk of the mutations (81.5%) were restricted 
to the D-loop region, while other mutations were detected in the 16S rRNA, ND2, and ATPase 6 
genes. Of these mutations, five (42%) were deletions or insertions in a homopolymeric C-stretch 
between nucleotides 303–315 (D310) within the D-loop. The remaining seven mutations (58%) 
were single-base substitutions in the coding or non-coding regions (D-loop) of the mitochondrial 
genome (Tan et al., 2002).  
In another study, somatic mutations were detected in 61% (11/18) of the fine needle aspirates 
from primary breast tumors harbored mtDNA mutations that were not detected in matched 
lymphocytes from the same patient or in age-matched normal breast tissue and most of the 
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mutations identified were in the D-loop region. While 42% of the mutations were present in the 
homopolymeric C stretch D310 region encompassed within the control region (D-loop). In 39% 
(7 of 18) somatic mutations in ND and cytochrome b genes were present. Again, these mutations 
were all homoplasmic suggesting a high clonal stability (Parrella et al. 2001). Zhu and colleagues 
could detect mutations in as much as 93% (14 of 15) of the examined breast tumor cells. Many of 
these tumors had multiple mtDNA mutations and the relative mutation frequency in D-Loop 
mutations was seven fold higher compared to that in gene coding areas (Zhu et al. 2005). 
As observed in the aforementioned study, it has been found in a study with paired tumorous and 
nontumorous breast tissues from 60 patients 30% breast cancers displayed somatic mutations in 
mtDNA D-loop region. The occurrence of D-loop mutations was associated with an older onset 
age ( 50 years old), and tumors that lacked expressions of estrogen receptor and progesterone 
receptor and significantly poorer disease-free survival (Tseng et al. 2006). It was indicated a D-
loop mutation is a significant marker independent of other clinical variables. A study on somatic 
mutation in the D-loop region of mtDNA has revealed that insertions or deletions at nucleotide 
position (np) 303-309, a polycytidine stretch (C-tract) termed D310, are the most common 
mutations of mtDNA in human cancers including breast cancer (Tan et al. 2002). In addition, it 
has been also reported that breast cancers harbouring mutations in D-loop region, particularly at 
the polycytidine stretch or close to the replication origins of the heavy-strand, had a significantly 
lower copy number of mtDNA than the ones without D-loop alterations (Man et al. 2007). 
Although the most common mtDNA mutations detected in breast cancer have been largely single 
base substitutions or insertions, a large deletion of 4977 bp has been detected in both the 
malignant and paired normal breast tissues of patients with breast cancer (Sharp et al. 1992, 
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Bianchi et al. 1995). The incidence of the 4,977-bp deletion in nontumorous breast tissues (47%) 
was much higher than that in breast cancers (5%) (Tseng et al. 2006).  
 
All together, these observations suggest that somatic mutation in the D-loop of mtDNA can be 
considered as a new prognostic marker for some types of cancers, and that mtDNA mutations 
may play a role in cancer progression and in response to anticancer drug treatment. 
 
In addition to alterations on the sequence of mitochondrial genome, a decrease in mtDNA copy 
number was found to associate with an older onset age (≥ 50 years old) and a higher histological 
grade of breast cancer. In addition, patients with reduced mtDNA content had significantly poorer 
disease-free survival and overall survival rate (Yu et al. 2007). In breast cancer it was reported 
that mtDNA content is reduced in 80% cases relative to normal controls (Mambo et al 2005). 
These results suggest that reduction in the content of mtDNA may be involved in neoplastic 
transformation or progression of breast cancers. However, no similar association was found in 
other studies of breast cancer patients (Tseng et al. 2006, Mambo et al. 2005).  
 
3.2 MtDNA as a potential biomarker for breast cancer 
 
 
Earlier diagnosis and treatment of breast cancer play an important role in reducing mortalities 
(Pantel et al. 2003). Many researchers attempted to establish molecular biological and 
immunological methods for detection of individual metastatic breast cancer cells in peripheral 
blood and bone marrow (Zhong et al. 1999a, Diel et al. 2000). However, a human eukaryotic cell 
containing only one or two copies of each gene limited the sensitivity of using genomic 
alterations as markers on the nuclear DNA level to identify single tumour cells in circulation. 
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Lack of cancer specific markers limited the specificity of using mRNA and proteins for gene 
expression analysis to distinguish normal and malignant cells (Zhong et al 1999b). Therefore, 
there is no reliable screening test for early diagnosis of breast cancer which measures less than 
2mm, and there are no well-established measures to screen for micrometastases. 
 
 
It has been shown that early diagnosis and accurate identification of haematogenic metastasic 
tumor cells in breast cancer can improve the success of treatment and patients' survival time. The 
ideal tumor biomarkers in the peripheral circulation could provide a better solution on the 
management of cancer. The ideal biomarkers for cancer can be sensitive detection markers for 
screening and earlier diagnosis, classification markers for treatment selection, and clinical 
response markers and risk assessment markers for monitoring and follow up of cancer patients 
(Fig 3). 
 
                            
 
Figure 4. Biomarkers as potential tools for clinical applications. 
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More biomarkers are still needed to apply to the clinical implementation of cancer. Estrogen 
receptor and HER-2/neu status in breast tumours are currently routinely used as a guide for 
adjuvant therapy. As more new anticancer agents are being developed, more new biomarkers 
need to be found to aid in the detection of micrometastasis and to guide treatment using the new 
agents. However, there are still many obstacles to developing clinically useful biomarker tests for 
routine clinical practice. A lack of tumour marker specificity and lack of sensitivity of testing 
systems limit their clinical use.  
 
The instabilities and alterations of mtDNA in tumorigenesis may serve as earlier markers for 
cancer development and may have the potential for tracking tumour progression and tumour 
metastasis. A human eukaryotic cell contains hundreds or thousands of mitochondria and each 
mitochondrion contains 1-10 copies of mtDNA. In addition, three facilities of mtDNA make it 
have an application value for. The first, the high copy number in comparison with the nuclear 
DNA enables detection of rare target cells, even at low levels. The second, mutant mtDNA has 
been reported to be 10-200 times more abundant than mutated nuclear DNA in cancer cells 
(Jackson et al. 2002; Hood et al. 2003; Petros et al. 2005), suggesting that they may be of 
promising clinical utility. The third, it has been showed that elevated mtDNA level is present in 
plasma of prostate cancer patients with a poor survival. Amplification of mitochondrial nucleic 
acids shows increased sensitivity and specificity over genomic DNA as diagnostic and prognostic 
marker in prostate cancer patients (Mehra et al 2007). Altogether, the properties of mtDNA, such 
as high copy numbers, high prevalence of mutations and quantitative and qualitative alterations in 
cancer, encourage us to investigate the clinical relevance of mtDNA alterations in cancers. In 
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addition, the simple structure and short length of mtDNA makes the genome-wide screening of 
mtDNA in life science easier and more cost-effective than using nuclear DNA.  
 
In the last decades, a number of studies have been carried out on the investigation of mtDNA as a 
potential biomarker for cancer. Furthermore, the high frequency of mtDNA alterations in cancer 
and their presence in the early stages of disease could possibly be exploited as clinical markers 
for early cancer detection (Modica-Napolitano et al. 2002).  
 
To measure the plasma mtDNA, or cell-free nucleic acid, has been entertained as a prognostic 
marker. Plasma mtDNA could be defined as fragments of mtDNA that were detectable in the 
extracellular fluid. Recent studies demonstrated that circulating mtDNA mutations can be 
detected in melanoma, prostate cancer, colon cancer, hepatocarcinoma, and pancreatic carcinoma. 
To assess whether such mtDNA mutations could be detected mutations in women with breast 
cancer, and the possibility to aid in the diagnosis of breast cancer,  a study has been performed 
with 27 paired samples (14 patients with breast cancer and 13 healthy controls) of white blood 
cells and serum. The mtDNA D-loop region was amplified and sequenced. Polymorphisms were 
detected in all specimens, but no mtDNA mutations were found in any of the study groups 
(Losanoff et al. 2008). It has been suggested that the method used in this study are extremely 
sensitive in polymorphism detection, but could not detect mtDNA mutations in the blood of 
women with breast cancer.  
 
Indeed, tumor-derived circulating nucleic acids in the plasma and serum of cancer patients have 
been sought as a noninvasive tool for cancer detection over one decade. Though the test criteria, 
sensitivity and specificity, compare favorably with conventional diagnostic measures, to date the 
methodical tediousness of circulating nucleic acids analysis prevented it from becoming a clinical 
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routine application. But, with speeding development of state-to-art technology towards automated 
high-throughput platforms, it would not be surprised in the nearby future to see analyses of 
circulating nucleic acids in plasma and serum becoming routing methods for diagnosis and 
follow-up monitoring of cancer patients. The dream is that the application of circulating nucleic 
acids in plasma and serum as a cancer biomarker and potential profiling tool will finally translate 
into a longer survival and better quality of life for cancer patients. 
 
However, the role of mtDNA mutations in cancer development, genetic instability and disease 
progression, and the development of drug resistance remains ambiguous, which warrants a 
comprehensive investigation in blood and tissue samples of patients with breast cancer as well as 
in healthy people. 
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1. Study aim and experimental design 
 
 
Aim 
In order to establish a test system for facilitating the early detection and monitoring of breast 
cancer and its metastasis, we will investigate: 
i. Whether any quantitative and qualitative alterations of mitochondrial DNA 
(mtDNA)   exist in breast cancer. 
ii. Whether tumour cell or/and tumour-derived mtDNA shedding from tumour tissues                   
      into peripheral blood could serve as sensitive and specific markers for clinical                           
      application in screening, monitoring and follow-up of breast cancer. 
 
 
Experimental design 
We first intend to investigate quantitative alteration and qualitative alteration of mtDNA in breast 
cancer tissue. Tumour-specific mtDNA alterations will be used as markers to identify tumour-
derived cell free and cellular DNA in the blood samples of patients with breast cancer.  The 
relative proportion of tumour derived and non-tumour derived mtDNA will be detected by 
MALDI-TOF mass spectrometry assay. The levels of cell-free tumour derived and non-tumour 
derived mtDNA in three study groups, namely, breast cancer, breast benign lesion and healthy 
control, will be compared. The association between levels of tumour-derived mtDNA in 
peripheral blood and traditional clinical parameters, such as tumour size, lymph node 
involvement, and extent of metastasis, histological grade, receptor status and HER’s-2/neu status 
will be analyzed.  
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2.   Summary of background 
 
 
 
2.1 Instability of mitochondrial genome  
 
Eukaryotic cells have a nuclear genome and additional cytoplasmic genomes that are 
compartmentalized in the mitochondria. The human mitochondrial genome is a circular double 
stranded DNA of 16.6 kb, including the coding regions for 13 respiratory chain protein subunits 
and the hypervariable non-coding D-loop regions (Anderson et al 1981; Fernandez-Silva et al. 
2003). The mitochondria produce energy to support cellular activities and also generate reactive 
oxygen species (ROS).  
 
In comparison to nuclear genomic DNA,  
• MtDNA molecules are markedly exposed to ROS (ROS enhanced aggression).  
• Due to the lack of protective histone proteins, mtDNA is highly sensitive to oxidative 
DNA damage by ROS (high sensitivity to damage).  
• The replication and repair of mtDNA depend on nuclear genes (deficient repair of 
damage). 
• The limited DNA repair mechanism allows mtDNA mutations to accumulate (high rate 
of mutations).  
Thus, the properties of mtDNA suggest their potential importance in aging, apoptosis and 
especially carcinogenesis (Augenlicht et al 2001; Bartnik et al. 2001, Bianchi et al. 2001). 
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2.2 MtDNA and human cancers 
 
MtDNA aberrations, which include point mutations, instability of mono- or dinucleotide repeats, 
mono- or dinucleotide insertions, deletions or quantitative alterations, have been found in  
•  solid tumours, such as colon, stomach, liver, kidney, bladder, prostate, skin and lung    
        cancer (Chatterjee et al, 2006; Brandon et al 2006), 
•     hematologic malignancies, such as leukaemia and lymphoma (Fontenay M et al. 2006).  
The instability of mtDNA may play an important role in tumor development.  A high rate of 
mutation, the presence of most of the mutations in coding sequences, their subsequent 
accumulation because of limited repair mechanisms, and insertion of mutations into nuclear DNA 
have all been noted in mtDNA.  
For instance: 
• MtDNA mutations in coding sequences have been found in pre-malignant histological 
benign-appearing glands of the prostate, implying that the mtDNA alterations might be 
involved in the early events of prostate cancer development (Jeronimo et al 2001).  
• A high prevalence of mtDNA mutations in colorectal cancer tissues, with lower numbers 
in the pre-cancerous lesions and no mutations in the surrounding normal tissues have been 
observed, suggesting that, while the histology appears pre-malignant, the genotype is 
moving towards the tumour state (Akhionbare et al. 2004).  
• Ultraviolet radiation in sunlight is an important factor in the development of skin cancer 
and has been shown to induce mtDNA damage in human skin, which could not be 
repaired in mitochondrial genomes (Pascucci et al. 1997; Croteau et al. 1997).   
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2.3 MtDNA and breast cancer  
 
Breast cancer is the most common malignant disease in women of Western industrial countries.  
There have been a variety of mtDNA alterations found in breast tumour tissues: 
 
• Tan et al. (2002) performed an analysis of all known mtDNA genome mutations. They 
could identify 27 mtDNA mutations in 74% of patients with breast cancer. The 
mutations were located in coding regions, and mostly in the hypervariable D-loop 
regions.  
• Zhu et al. (2005) found mutated mtDNA in 93% of breast cancer tissues, with the 
frequency of mutations higher in the coding regions and D-loop regions than in other 
loci tested. 
• Breast cancer-specific deletions of mtDNA have been observed in 77% of breast cancer 
tissues by Zhu et al. (2004) and in 46% of breast cancer tissues by Dani et al. (2004). 
• In the fine-needle aspirates of patients with breast cancer, Parrella et al. (2001) found 
mtDNA mutations in 61%, deletions or insertions in 42% and single base 
substitutions in 58%, which were localized in the coding and D-loop regions.  
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3   Quantitative analysis of mtDNA in breast cancer  
 
3.1 Method setup for quantitative analysis 
Eukaryotic cells have nuclear DNA (nDNA) and additional cytoplasmic mitochondrial DNA 
(mtDNA). It has been demonstrated that cell-free nucleic acids, i.e., cell-free (ccf) nuclear DNA 
(cf-nDNA) and ccf mtDNA exist in circulation (Sozzi et al., 2003). Quantification of circulating 
nucleic acids in plasma and serum could be used as a non-invasive diagnostic tool for monitoring 
a wide variety of diseases and conditions. We describe here a rapid, simple and accurate 
multiplex real-time PCR method for direct synchronized analysis of circulating cell-free (ccf) 
mitochondrial (mtDNA) and nuclear (nDNA) DNA in plasma and serum samples. The method is 
based on one-step multiplex real-time PCR using a FAM-labeled MGB probe and primers to 
amplify the mtDNA sequence of the ATP 8 gene, and a VIC-labeled MGB probe and primers to 
amplify the nDNA sequence of the glycerinaldehyde-3-phosphate-dehydrogenase (GAPDH) 
gene, in plasma and serum samples simultaneously. The efficiencies of the multiplex assays were 
measured in serial dilutions. Based on the simulation of the PCR reaction kinetics, the relative 
quantities of ccf mtDNA were calculated using a very simple equation. Using our optimised real-
time PCR conditions, close to 100% efficiency was obtained from the two assays. The two assays 
performed in the dilution series showed very good and reproducible correlation to each other. 
This optimised multiplex real-time PCR protocol can be widely used for synchronized 
quantification of mtDNA and nDNA in different samples, with a very high rate of efficiency.  
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Figure 5. Simulation of real-time PCR kinetics for amplifying mtDNA and nDNA on a serials of 
dilutions. The figure shows reproducible standard dilution curves for identification of the mtDNA 
and nDNA. The upper lines are nDNA standard dilution curves and the lower lines are mtDNA 
standard dilution curves. The numbers on the y axis represent the values of cycle threshold (Ct) 
and numbers on the x axis represent the dilution points. 
                      
Figure 6. MtDNA content in paired adjacent normal and cancerous breast tissue. The content of 
mtDNA in cancerous tissues is significantly lower than that in normal tissues (Mann–Whitney U 
test P < 0.001) 
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3.3 MtDNA quantification in cancer tissues of patients with breast cacner 
 
Human cells contain a nuclear genome and additional cytoplasmic genomes that are 
compartmentalised in the mitochondria. In contrast to nuclear DNA, mitochondrial DNA 
(mtDNA) reveals high mutation rates caused by constant exposure to mutagenic oxygen radicals 
and lacks the protective mechanisms of DNA repair. These properties of mtDNA suggest their 
potential importance in ageing, apoptosis and especially carcinogenesis (Zhang and Qi 2008; 
Zhang et al. 2008). Quantitative aberrations of mtDNA have been observed in various sample 
types from patients with cancers (Mambo et al. 2005). While increased mtDNA content has been 
found in prostate (Mizumachi et al. 2008a), head and neck (Kim et al. 2004), endometrial 
adenocarcinoma (Wang et al. 2005), etc., reduced mtDNA content in renal (Meierhofer et al. 
2004) and liver cancers (Yin et al. 2004) has been reported. Because of these mutations and the 
quantitative aberrations involved in the development of human cancers, mtDNA may have 
promising clinical applications for cancers (Jiang et al. 2005; Jain et al. 2007). Using the 
established multiplexed assay, we found down-regulated mtDNA in breast cancerous tissues 
compared to the paired breast normal tissues from 51 patients with breast cancer. The amounts of 
nDNA and mtDNA in 102 tissue samples were quantified for both glyceraldehype-3-
phosphodehydrogenase (GAPDH) gene and mtDNA encoded ATPase (MTATP) 8 gene. The 
average threshold cycle (Ct) number values of the nDNA and mtDNA were used to calculate 
relative mtDNA content in breast tissues. The median delta Ct (∆Ct) and the median mtDNA 
content for normal and cancerous breast tissues were 6.73 and 2.54, as well as 106.50 and 5.80 (P 
= 0.000 respectively). MtDNA content was decreased in 82% of cancerous breast tissues 
compared with the normal ones. The changes were associated with hormone receptor status. Our 
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finding suggests that decreased mtDNA content in breast cancer may have diagnostic and 
prognostic value for the disease.  
 
3.3 MtDNA quantification in whole blood of patients with breast cancer 
 
Alterations of mtDNA have been implicated in carcinogenesis. MtDNA alterations were also 
detected in bodily fluids, suggesting that mtDNA changes might serve as sensitive early 
biomarker for non-invasive detection of several types of solid cancer including breast cancer 
(Fliss et al. 2000). We sought to investigate whether mtDNA content in the peripheral blood of 
breast cancer patients is associated with clinical and pathological parameters. Using an accurate 
multiplex quantitative real-time PCR for synchronized determination of mtDNA and nuclear 
DNA, we found down-regulated mtDNA in the whole blood samples from in stage I breast 
cancer patients, compared to normal controls and advanced breast cancer patients (P = 0.023).  
Reduced mtDNA was found often in post menopausal cancer group (P = 0.024). No difference in 
mtDNA content, in regards to age (p =0.564), lymph node involvement (p = 0.673), ER (p = 
0.877), PR (p = 0.763), and Her-2/neu expression (p = 0.335), was observed. In the present study, 
decreased mtDNA content in the peripheral blood of patients with breast cancer was strongly 
associated with stage I. The use of mtDNA may have value for earlier diagnosis of breast cancer.  
Due to the unclear mechanism of compensated mtDNA quantities in advanced stage breast 
cancer, further studies are required to clarify the biology of the phenomena (Xia et al 2009, 
revision submitted). 
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Figure 7. Box plot analysis illustrating levels of mtDNA in peripheral blood of normal group and 
breast cancer groups according the stage of carcinomas. The quantitative mtDNA content (as 
described in the text) is shown on the Y axis. The mtDNA content in peripheral blood of stage I 
breast cancers is significant lower than in the other stages as well as in normal control group 
according the One-way ANOVA on the ranks (*P = 0.018). Horizontal lines: group medians; 
boxes: boxes: 25–75% quartiles; boxes: 25–75% quartiles, range, peak and minimum. 
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3.4 MtDNA quantification in plasma of patients with breast cancer 
 
The discovery of circulating cell-free (ccf) DNA in circulation has opened up the possibilities of 
non-invasive diagnosis and monitoring of a wide variety of malignant diseases. With the aim to 
simplify cancer management, cancer research lately dedicated itself more and more to discover 
and develop non-invasive biomarkers. In this connection, circulating cell-free (ccf) DNA seems 
to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and mitochondrial DNA 
(mtDNA) have been found in several cancer types and might have a diagnostic value. Using 
multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples 
from patients with malignant and benign breast tumors, and from healthy controls. While the 
levels of ccf nDNA in the malignant disease group were significantly higher in comparison with 
the benign group and the healthy control group, lower level of ccf mtDNA was found to be 
elevated in the two tumour-groups. A cut-off value selected by ROC curve could allow 
distinguishing between the breast cancer cases and the healthy controls using ccf nDNA as 
marker and between the breast tumour group and the healthy controls using ccf mtDNA as 
marker. Our data suggest that both species might have a potential as biomarkers in breast tumor 
management. However, ccf nDNA seems to be the stronger biomarker regarding sensitivity and 
specificity (Kohler et al. 2009, submitted). 
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Figure 8.  ROC curves using ccf nDNA and mtDNA for discriminating between the study-
groups. A) ROC curve of ccf nDNA for discriminating between the cancer group and the healthy 
control group (sensitivity = 81 %; specificity = 69 %). B) ROC curve of ccf mtDNA for 
distinguishing between the tumor  group and the healthy control group (sensitivity = 53 %; 
specificity = 87 %). 
 
4. Qualitative analysis of mtDNA in breast cancer 
4.1 Method setup for qualitative analysis 
MtDNA is a circular cytoplasmic double stranded DNA of 16.6 kb, including the coding regions 
and the hypervariable non-coding D-loop region (Anderson et al. 1981, Fernandez-Silva et al. 
2003). The features of mtDNA, such as matrilineal inheritance, high copy numbers per cell and 
lack of recombination make it a powerful tool in life science. Single nucleotide polymorphisms 
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(SNPs) of mitochondrial DNA (mtDNA) are involved in physiological and pathological 
conditions. Because of the importance of mtDNA SNPs in life science, a rapid, accurate, highly 
sensitive and high-throughput approach with low cost to identify physiologic and pathogenic 
mtDNA variants is needed for the analysis of large-scale samples, multiple SNPs or rare mtDNA. 
Hence we developed uniplex and multiplex assays for mtDNA SNP detections by using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The 
detection limit achieved with the assays corresponded to the identification of five-genome 
equivalence of mtDNA per reaction after first round PCR amplification. The testing system 
enabled the discrimination of as little as 5% of mtDNA polymorphism in the predominating 
background of mtDNA not containing the SNP. No false positive and false negative results were 
obtained using the uniplex and multiplex MALDI-TOF MS assays for the analysis of the 18 
SNPs compared with those obtained by sequencing analysis (Fan et al. 2007). Based on the 
successful uniplex assay, we developed a multiplex assay allowing analysis of 22 mtDNA SNPs 
in a single reaction, which as well demonstrated very high efficiency as expected (Fan et al, MS 
in preparation). This novel application enables the rapid, sensitive and accurate identification of 
single or multiple mtDNA SNP variants in a single reaction, which could serve as a powerful and 
sensitive tool for the studies including forensic medicine, tracing of matrilineage, transplantation 
immunology, transfusion medicine, the diagnosis of mtDNA mutation related disorders, and the 
research  regarding aging, apoptosis and carcinogenesis based on physiologic and pathogenic 
alterations of mtDNA for the analysis of large-scale samples, multiple SNPs or rare mtDNA. 
  59 
. 
 
Figure 9. Comparison of MALDI-TOF and sequencing analysis for the sensitivity test. MtDNA 
sample containing the SNP of ‘‘T’’ at the position of 462 was mixed into the mtDNA sample 
containing a ‘‘C’’ at the same position. Panel (A) shows the results by MALDI-TOF MS and 
sequencing analysis for the mixture of 50%–50%. Panel (B) shows the results by MALDI-TOF 
MS and sequencing analysis for the mixture of 5%–95%. 
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Figure 10.  Mass spectra of mtDNA 22plex assay. Mass peaks of unextended extension primers 
and different alleles were labelled in different colours. 
 
4.2 Method validation with HPA study by sequencing 
 
Genotyping of single nucleotide polymorphisms (SNPs) using matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is an emerging 
technique, where finally tools for end users have become available to design primers and analyze 
SNPs of their own interest. This study investigated the potential of this technique in platelet 
(PLT) genotyping and developed a validated method for genotyping of clinical relevant human 
PLT antigens (HPAs). A multiplex assay using MALDI-TOF MS to analyze six HPA loci (HPA-
1, HPA-2, HPA-3, HPA-4, HPA-5, and HPA-15) simultaneously in a single reaction was applied 
for the genotyping of 100 DNA samples from a cohort of plateletpheresis donors and a patient 
population (n = 20) enriched for rare alleles. The genotyping results using MALDI-TOF MS 
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were validated by the comparison with the results from typing by polymerase chain reaction with 
sequence-specific primers and conventional DNA sequencing. Both homozygous and 
heterozygous genotypes of HPA-1 to -5 and -15 of the 120 individuals were easily identified by a 
six-plexed assay on MALDI-TOF MS. The three approaches achieved a 100 percent concordance 
for the genotyping results of the six HPA loci.Compared to conventional methods, the MALDI-
TOF MS showed several advantages, such as a high velocity, the ability to perform multiplexed 
assays in a single reaction, and automated high-throughput analysis of samples. This enables 
cost-efficient large-scale PLT genotyping for clinical applications. 
 
   
 
Figure 11. By using MALDI-TOF MS based MicroARRAY multi-plex assay, 100% concordance 
has been achieved for the genotyping of the 6 HPAs by the comparison with the results from 
typing by polymerase chain reaction with sequence-specific primers and conventional DNA 
sequencing. 
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4.3 MtDNA mutations in breast cancer 
 
Mutations and up-/down-regulations of mitochondrial DNA (mtDNA) have been found in various 
cancers (Singh et al. 2007). The mtDNA alterations are suspected to be associated with 
carcinogenesis. However, the clinical relevance of the finding remains unknown and multiplexed 
assays for simultaneously detecting multiple mutations of mtDNA in a single reaction are 
currently not available. By using the microarray chip based multiplex assay using matrix-assisted 
laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS), we detected 22 
mtDNA single nucleotide variants simultaneously in 6 breast cancer cell lines and in the 102 
cancerous and adjacent breast tissue samples from 51 patients with breast cancer. Totally, 164 
mutations were identified in 66.67% of breast cancer cell lines and in 49.12% patients’ tissue 
samples, in both the cancerous and adjacent parts. Most of the detected mtDNA variants in breast 
cancer samples were distributed in the regions of D-loop, 12S ribosomal RNA, 16S ribosomal 
RNA and tRNA. We also investigated the relationship between the quantitative and qualitative 
alterations of mtDNA in breast cancer. No correlation was found between the down-regulation 
and the mutations of mtDNA in breast cancer tissues. Similarly there was no association was 
found between the mutations and clinic-pathological parameters including tumour type, tumour 
size, lymph node involvement, extent of metastasis, stage, histological grading, and ER, PR, and 
HER-2/neu receptors.  Our study suggests that down-regulation and mutations of mtDNA in 
breast cancer tissues may be resulted by different mechanism. Both the qualitative and 
quantitative alterations of mtDNA in breast cancer may serve as biomarkers independent of 
clinic-pathological parameters for breast cancer on early screening, diagnosis, monitoring 
treatment effects, prognosis, and follow up. MALDI-TOF MS based MicroARRAY multiplex 
  63 
assay is a high-throughput, and cost-efficient tool for large scale allelotyping of mtDNA 
mutations in life science.  
 
Sample 
counting 
 
Sample ID 
 
characteristics  
Nucleotide position 
(np) Adjacent Cancer (Cell line) 
1 MDA-MB 231  709  A 
2 MCF-7  2706  A 
3 BT 549  2706  A 
4 SKBR 3  2706  A 
1 802 IDC 709 A A 
2 803 IDC 2706 A A 
3 804 ILC 16145 A A 
4 807 IDC 16145 AG A 
5 812 IDC 16145 AG  
 812 IDC 709  A 
6 815 AMC 2706 A A 
7 817 IDC 16145 A A 
8 819 IDC 709 A A 
9 821 IDC 16145 A A 
10 822 IDC 311-315 C ins/- C ins/- 
11 823 IDC 709 A A 
 823 IDC 2706 A A 
12 824 ILC 709 A  
13 825 IDC 16145 A A 
14 827 IDC 15924 G G 
15 828 IDC 16145 AG A 
16 829 IDC 709 A  
17 830 IDC 15924  G 
18 838 IDC 15924 G G 
19 840 IDC 709 A A 
20 841 IDC 311-315 C ins/- C ins/- 
21 843 IDC 2706 A A 
22 844 IDC 16145 AG  
 844 IDC 15924  G 
23 846 IDC 16145 A  
24 851 IDC 15924 G G 
25 853 IDC 709 A A 
 
Table 4.  mtDNA sequence variants were found in tissue samples. *Besides 822n/p and 841n/p 
paired samples only have one of C ins/- heteroplasmic mutations, each of the rest samples and 
cell lines have one mutation of C ins.  (IDC = invasive ductal carcinoma, ILC=invasive lobular 
carcinoma, AMC=atypical medullary carcinoma). 
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5.   Correlation Studies  
 
5.1 Correlation study between quantitative and qualitative changes of mtDNA in tissues 
 
Mitochondrial DNA alterations were long suspected to associate with carcinogenesis. Both 
alterations of mtDNA content and the mtDNA sequence have been detected in breast cancer, 
while it is clear yet whether the two alterations are correlated to each other. Using the MALDI-
TOF MS based and multiplex MicroARRAY assay, 22 somatic mtDNA mutations were 
simultaneously detected in a single reaction. Six breast cancer cell lines and 102 cancerous and 
adjacent breast tissue samples from 51 patients with breast cancer were studied. Most of the 
detected mtDNA variants in breast cancer samples were distributed in the regions of D-loop, 12S 
ribosomal RNA, 16S ribosomal RNA and tRNA. In our previous study, we found down-
regulation of mtDNA in the breast cancerous tissues compared to the adjacent tissues. In this 
study, we investigated the relationship between the quantitative and qualitative alterations of 
mtDNA in breast cancer. No correlation was found between the down-regulation and the 
mutations of mtDNA in breast cancer tissues. Also there was no association was found between 
the mutations and clinic-pathological parameters including tumour type, tumour size, lymph node 
involvement, extent of metastasis, stage, histological grading, and ER, PR, and HER-2/neu 
receptors. 
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Group 
 
Case (percentage) mtDNA content P value 
 
709- 89 (87.25) 15.35 (1.17-69272.73) 0.098* 
 
709+ 13 (12.75) 56.69 (1.56-2730.60)  
 
2706- 94 (92.16) 15.19 (1.17-69272.73) 0.700* 
 
2706+ 8 (7.84) 39.98 (1.49-2730.60)  
 
15924- 94 (92.16) 15.19 (1.17-69272.73) 0.429* 
 
15924+ 8 (7.84) 63.60 (2.17-13587.57)  
16145- 
 
86 (84.31) 21.05 (1.17-69272.73) 0.800* 
 
16145+ 16 (14.71) 13.27 (1.35-749.61)  
 
Var - 60 (58.82) 9.73 (1.17-69272.73) 0.039* 
 
Var+ 42 (41.18) 37.42 (1.35-13587.57)  
 
1N & Var - 28 (27.45) 60.38 (3.05-9877.98) 1vs2: 0.130*; 3vs4: 0.070* 
 
2N & Var+ 23 (22.55) 216.02 (1.35-3888.51) 1vs3: 0.000*; 2vs4: 0.013* 
 
3C & Var - 32 (31.37) 3.89 (1.17-69272.73) 0.421** 
 
4C & Var+ 19 (18.63) 15.03 (1.49-13587.57)  
 
 
Table 5. Sample profile of mtDNA content and variant groups (excluding 311-315). N: normal; C: 
cancerous; Var: Sequence Variant; “-”: without; “+”: with. * Mann-Whitney U test in normal 
tissue; **Chi-square test was applied to analyze the association between tissue type and mutation. 
 
5.2 Correlation study between mtDNA content in paired blood and in tissue samples    
Using multiplex quantitative Real-Time PCR, we investigated the levels of nDNA and mtDNA in 
10 paired plasma and tissue samples from patients with breast carcinomas. The median delta Ct 
(∆Ct) and median mtDNA content for plasma and cancerous tissues were 5.79 and 5.03, as well 
as 374280.44 and 13918579.50 (P = 0.005). While the mtDNA contents in the tissue are 
correlated with those in plasma (Spearman's rank correlation coefficient ρ = 0.648, P = 0.043)  
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Figure 12. MtDNA contents in tissue are correlated with those in plasma (ρ=0.648, P=0.043). 
 
5.3 Correlation study between mtDNA content in paired blood and in tissue samples 
Most mtDNA polymorphisms have been identified in the displacement loop (D-loop) region 
harbouring the major promoters responsible for replication and transcription. Likewise in one 
previous study we found mtDNA polymorphisms at the region around D-loop in paired breast 
cancer tissue samples. It is not know yet whether different mtDNA variants found in the breast 
cancer tissue can also be found in the correspondent plasma. This study is to be targeted on the 
identification of mitochondrial DNA (mtDNA) polymorphisms in three hyperviable region in 
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breast cancer patients and the investigation on the role of mtDNA mutation in tumorigenesis. 
Paired plasma and tissue samples from 10 unrelated patients with breast cancer were analyzed for 
mtDNA nucleotide variations in three hyper variable regions of mtDNA, by the polymerase chain 
reaction-single strand conformation polymorphism (PCR-SSCP) method using 4 pairs of primers 
followed by direct DNA sequencing. 221 homoplasmic variants but no any heteroplasmic ones 
were detected at 65 nucleotide positions (np) in 10 paired samples. Each of these 20 samples 
displayed at least 6 mtDNA allelic variants. Of all the variants, 70 variants were detected in 
plasma samples but not in paired tissue samples. Reversely, 49 variants were identified in tissues 
samples but not in paired plasma samples (Table 6). 
 
It has been proposed the plasma mtDNA, or cell-free mtDNA, could be use in tracking the tumor 
derived mtDNA shedding from tumour tissues into peripheral blood. The divergence between 
mtDNA mutations present in plasma and those in tissue could be caused by tumor, and might 
serve as a specific biomarker for tumor diagnosis, prognosis and follow-up. All the mutations 
detected in this study are homoplasmic, and no any heteroplasmic was present, which indicated 
no tumor metastasis occurred. The heteroplasmic condition was not detected in plasma might be 
due to the mutant allele present in a very low frequency compared to the wild type allele. Our 
method is not sensitive enough to detect lower than 2% mutant DNA from wild type background. 
The development of novel techniques, for example digital PCR and BEAMing-up method, might 
conquer this difficulty, but it is either too expensive, or too complicated, or both to expand it to 
routine application.  
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Sample ID Nucleotide position 
Reference 
sequence Plasma Tissue 
16290 C T C 
16295 C C T 
16319 G A G 
146 T T C 
235 A G A 
303-309 6C 6C 7C 
308 C T C 
310 T DEL T 
489 T T C 
701 
514-523 5CA 6CA 4CA 
16051 A G A 
16129 G G A 
16189 T C T 
16257 C C T 
16261 C C T 
16362 T C T 
152 T C T 
235 A G A 
456 C T C 
702 
489 T C C 
16126 T T C 
16234 C C T 
16290 C C T 
16304 T C T 
16319 G G A 
189 A A G 
198 C T C 
235 A A G 
249 A DEL A 
703 
303-309 7C 8C 9C 
16126 T C T 
16163 A G A 
16186 C T C 
16189 T C T 
16924 C T C 
16304 T T C 
152 T C T 
195 T C T 
207 G G A 
248 A A DEL 
704 
303-309 6C 7C 6C 
16051 A A G 705 
16092 T T C 
  69 
16129 G A G 
16140 T C T 
16145 G G A 
16166 A G A 
 16189 T C T 
16217 T C T 
16245 C C T 
16257 C C T 
16274 G A G 
16261 C C T 
16293 A G A 
16335 A G A 
 
195 T C T 
16189 T T C 
16234 C T C 
16274 G G A 
146 T C T 
195 T C T 
706 
217 T C T 
16129 G G A 
16145 G G A 
16162 A A G 
16172 T T C 
16189 T C T 
16223 C T C 
16266 C T C 
16304 T T C 
16362 T C T 
146 T C T 
150 C T T 
248 A DEL A 
489 T C T 
707 
548 C C T 
16093 T C T 
16129 G G A 
16183 A DEL A 
16189 T DEL T 
16217 T C T 
16218 C T C 
16223 C C T 
16325 T T C 
16362 T T C 
56 A DEL A 
58 T A T 
72 INS - G - 
708 
94 G A G 
  70 
 303-309 7C 9C 7C 
16140 T T C 
16182 A DEL A 
16183 A DEL A 
16189 T C T 
16217 T C T 
16223 C C T 
16261 C T C 
16299 A G A 
16311 T C T 
16362 T T C 
193 A G A 
298 C C T 
303-309 7C 9C 7C 
489 T T C 
709 
514-523 5CA 4CA 5CA 
16129 G A G 
16140 T T C 
16162 A G A 
16172 T C T 
16182 A A DEL 
16183 A A DEL 
16189 T T C 
16217 T T C 
16274 G G A 
146 T T C 
150 C C T 
249 A DEL A 
514-523 5CA 4CA 5CA 
710 
548 C T C 
 
Table 6. MtDNA mutations found in 10 paired plasma and tissue samples. 
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6.  Prospect   
For the future plan regarding the research interest on mtDNA, the following issues need to be 
clarified: 
 The path-physiology and biology of mtDNA changes in cancer through detecting more 
clinical cases, investigating cell lines and/or establishing animal models 
 Whether the mtDNA changes in blood can be used for developing blood based test in 
clinical application in the aim of screening, earlier diagnosis, monitoring of patients with 
cancer 
 Whether the mtDNA changes in tissues can be used as classification markers for 
treatment selection 
 Whether the mtDNA changes in both blood and tissues can be used as clinical response 
markers and predictive markers for monitoring and following up of cancer patients. 
 The predictive and prognostic value of tumour derived mtDNA in peripheral blood should 
be evaluated. The dynamic process of the tumour derived molecules in circulation need to 
be investigated before, during and after clinical interventions such as chemotherapy. 
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Abstract 
With the aim to simplify cancer management, cancer research lately dedicated itself more and 
more to discover and develop non-invasive biomarkers. In this connection, circulating cell-free 
(ccf) DNA seems to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and 
mitochondrial DNA (mtDNA) have been found in several cancer types, suggesting that these two 
species might have a diagnostic value. 
Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma 
samples from patients with malignant and benign breast tumors, and from healthy controls. To 
evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing 
between the three study-groups we performed ROC (Receiver Operating Characteristic) curve 
analysis. We also compared the levels of both species in the cancer group with 
clinicopathological parameters.  
While the level of ccf nDNA in the cancer group were significantly higher in comparison with 
the benign tumour group and the healthy control group, the level of ccf mtDNA was found to be 
significantly lower in the two tumour-groups. The level of ccf nDNA was also associated with 
tumor-size. Using ROC curve analysis, we were able to distinguish between the breast cancer 
cases and the healthy controls using ccf nDNA as marker and between the tumour group and the 
healthy controls using ccf mtDNA as marker. 
Our data suggest that both species might have a potential as biomarkers in breast tumour 
management. However, ccf nDNA seems to be the stronger biomarker regarding sensitivity and 
specificity. 
 
Key words: Circulating cell-free DNA, mitochondrial DNA, breast cancer, real-time PCR 
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Introduction 
In several branches of biomedical research the quest for new disease-related biomarkers has 
become one of the main objectives [1-3]. When it comes to discover and develop new 
biomarkers, oncology seems to be the most ambitious field. During the last few years a lot of 
research has been done finding new cancer biomarkers with the aim to identify high risk 
individuals, detect cancer at an early stage, predict outcome, monitor and screen for disease 
recurrence [4]. In this respect the focus is now mainly directed towards the identification of non-
invasive cancer biomarkers [5, 6].  
In the case of breast cancer, there are a few non-invasive biomarkers for screening, predicting 
prognosis and monitoring that have come to routine clinical application [7]. Current established 
methods for routine breast cancer screening encompass in the first place non-invasive methods 
including clinical breast examination and imaging techniques like, mammography and 
ultrasonography [8]. However, in case of suspicion of breast cancer all these techniques have to 
be followed by histopathological analysis for which invasive procedures, such as biopsies, are 
needed.  
Lately, the discovery of circulating cell-free DNA (ccf-DNA) has sparked the interest of cancer 
scientists as it opens up a new possibility for non-invasive analysis of tumor derived genetic 
materials. Both, ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have become a 
matter of research and qualitative as well as quantitative alterations in these species have been 
implicated with cancer [9]. Changes in the level of ccf nDNA and mtDNA have been found in 
plasma and serum of patients with various cancer types [10, 11]. In breast cancer patients it has 
been shown that the ccf nDNA level is elevated in plasma as well as in serum when compared to 
healthy controls [12, 13]. On the other hand the mtDNA level was mostly found to be decreased 
in breast cancer patients in comparison with healthy controls [14, 15]. 
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To investigate the potential of ccf nuclear and mitochondrial DNA as a marker for clinical 
application we examined the level of both species in the malignant and benign tumour groups and 
healthy controls. 
 
Material and Methods 
The study was performed at the Laboratory for Prenatal Medicine and Gynaecological 
Oncology/Department of Biomedicine, Women’s Hospital Basel and approved by the local 
institutional review board (Ethic commission beider Basel). Written consent forms were collected 
from all patients who were involved in this study.  
 
Study cohort and sampling procedure 
The blood samples used in this study were collected in a time period from 2005 to 2007 in either 
the Women’s Hospital of the University of Basel or the Women’s Hospital of Liestal. In total 148 
women were included in the study. Most of the women were European Caucasians. All blood 
samples were taken before any surgical interventions or therapeutic treatments. Patients’ data 
(age, tumour size, lympmph node involvement, extend of metastasis, estrogen receptor, 
progesterone receptor and Her2neu - status) were obtained from the pathological reports. The 
blood samples were processed according to a standardized protocol which was described 
previously elsewhere [16].  
The study cohort (n=148) was divided into 3 groups: 1) malignant disease group (n=52); 2) 
benign disease group (n=26) and 3) healthy control group (n=70).  For groups 1 and 2 the 
diagnoses were all biopsy-confirmed. The healthy control group used in the study did neither 
have a history of cancer nor suffered from any other severe disease.  
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Real-time PCR 
For the simultaneous quantification of ccf nDNA and mtDNA from plasma a multiplex real-time 
PCR was performed using the Glyceraldehyd-3-phosphat-dehydrogenase (GAPDH) gene and the 
mtDNA encoded ATPase 8 (MTATP 8) gene. The sequences of primers and probes for the 
GAPDH and the MTATP 8 gene are shown as follows: GAPDH (forward): 5’ CCC CAC ACA 
CAT GCA CTT ACC3’; (reverse): 5’CCT AGT CCC AGG GCT TTG ATT 3’; probe5’ (MGB) 
TAG GAA GGA CAG GCA AC (VIC) 3’. MTATP 8 (forward): 5’ AAT ATT AAA CAC AAA 
CTA CCA CCT ACC 3’; (reverse): 5’ TGG TTC TCA GGG TTT GTT ATA 3’; probe: 5’ 
(MGB) CCT CAC CAA AGC CCA TA (FAM) 3’.  
The real-time RT-PCR was carried out in 25 µl of total reaction volume containing 7 µl H2O, 
12.5 µl TaqMan® Universal PCR Master Mix, 0.75 µl of each of the above mentioned primers, 1 
µl of the FAM-labeled MTATP 8-probe and 0.5 µl of  the VIC-labeled GAPDH-probe. For each 
reaction 1 µl of DNA was added resulting in a total reaction volume of 25 µl. The PCR was 
performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems) under 
the following conditions: an initiation step for 2 minutes at 50°C is followed by a first 
denaturation for 10 minutes at 95°C and a further step consisting of  40 cycles of 15 seconds at 
95°C and 1 minute at 60°C.   
For calibration a standard calibrator curve with known genomic DNA concentrations ranging 
from 3.125 x 104 to 10 pg/µL with a dilution factor of 5 (including 31250, 6250, 1250, 250, 50 
and 10 pg/µL) was used.  
 
Statistical Analysis 
All statistical analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, USA). The 
normality distribution of the data was determined using the Shapiro-Wilk-Test. The data were not 
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normally distributed. For the comparison of cff nDNA and mtDNA levels between the three 
groups (malignant disease group, benign disease group and healthy control group) the Mann-
Whitney-U-Test was performed. For the comparison of the ccf nDNA and mtDNA levels with 
other established prognostic factors the Mann-Whitney-U-Test and the Kruskal-Wallis-Test were 
used. P-values ≤ 0, 05 were considered statistically significant. 
 
Results 
Comparison of plasma ccf nDNA and mtDNA levels between the three study-groups 
We compared the levels of plasma ccf nDNA and mtDNA, analyzed by multiplex real-time PCR, 
between the malignant disease group, the benign disease group and the healthy control group. 
The level of ccf nDNA in the malignant disease group was significantly higher in comparison 
with the benign disease group (4678 vs. 1359, Mann-Whitney: P<0.001) and the healthy control 
group (4678 vs.1298, Mann-Whitney: P<0.001). No significant difference could be found in the 
level of nDNA between the benign disease group and the healthy controls (1359 vs. 1298 Mann-
Whitney: P=0.830).  
In contrast to the ccf nDNA determination, a decreased level of ccf mtDNA was found in the 
malignant disease group when compared with the healthy control group (205013 vs. 522115, 
Mann-Whitney; P=0.022) and the benign disease group (205013 vs. 73977; Mann-Whitney: 
P<0.001). However, the level of ccf mtDNA in the benign disease group is even significantly 
lower than that in the malignant disease group (73977 vs. 205013; Mann-Whitney: P=0.001). 
Median and range of plasma ccf nDNA and mtDNA are shown in Table 1. The comparison of the 
ccf nDNA and mtDNA levels between the study groups is depicted in Fig.1.  
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Correlation between the level of plasma ccf nDNA and mtDNA with clinicopathological 
parameters  
For the malignant disease group, the association between the level of ccf DNA and other 
established clinical parameters, including tumor size, lymph node involvement, extend of 
metastasis and the receptor status of estrogen receptor (ER), progesterone receptor (PR) and  
Her2/neu were analyzed.  
 
Association between plasma ccf DNA level and tumor size in the malignant disease group 
The level of ccf nDNA was significantly lower in the patients with breast cancer with a tumour 
size of less than two centimetres (<2 cm; n=21) than in those with a tumour size between 2 and 5 
centimetres (>2cm<5cm; n=25) (2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034). Only four 
patients with a tumour size of more than five centimetres (>5 cm) were recruited. There was no 
significant difference in the level of ccf nDNA between patients with a tumour size of more than 
five centimetres (>5 cm) and a tumour size from 2 to 5 centimetres (2 cm-5 cm). No association 
between the levels of ccf mtDNA and the tumor size could be found. The association between the 
ccf nDNA level and the tumor size is depicted in Fig.2. 
 
Association between plasma ccf DNA level and lymph node involvement, extend of metastasis, 
receptor status of ER, PR  and  Her2/neu amplification in the malignant disease group 
In the malignant disease group no statistical significance in the level of neither ccf nDNA nor 
mtDNA between node negative and node positive patients, extend of metastasis, receptor status 
of ER, PR and  Her2/neu amplification could be found.  
 
  119 
The applicability of plasma ccf nDNA and mtDNA as marker for the discrimination 
between the three study groups 
To evaluate the applicability of ccf plasma nDNA and mtDNA as a marker for distinguishing 
between the malignant, the benign disease groups and the healthy control group, we performed 
ROC (Receiver Operating Characteristic) curve analysis. For the identification of the optimal cut-
off point we used the Youden index (J).  J is the maximum vertical distance between the ROC-
curve and the diagonal reference line and is defined as J = maximum (sensitivity) + (specificity) – 
1. The Youden index allows the selection of an optimal cut-off point under the assumption that 
sensitivity and specificity are equally weighted [17].  
 
ROC curve analysis using ccf nDNA for the discrimination between the malignant disease group 
and the control group 
Level of ccf nDNA in the malignant disease group was significantly higher in comparison with 
the the healthy control group, but no significant difference was found in the level of ccf nDNA 
between the benign disease group and the healthy controls. For discriminating between the 
malignant disease group and the healthy control group, an optimal cut-off point was indicated at 
1866 GE/ml for plasma ccf nDNA with a sensitivity of 81 % and a  specificity of 69 % 
(AUC=0.80, P<0.001, 95% confidence interval=0.732-0.885). The ROC-curve for discrimination 
between the malignant disease group and the healthy control group using ccf nDNA is shown in 
Fig.3.  
 
ROC curve analysis using ccf mtDNA for the discrimination between the breast tumour group 
and the healthy control group 
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Decreased levels of ccf mtDNA was found in both, the benign disease group and the malignant 
disease group, when compared to the healthy control group. For discriminating between the 
breast tumour group (malignant and benign) and the healthy control group an optimal cut-off 
point was indicated at 463282 GE/ml for ccf nDNA with a sensitivity 53 % and a specificity of 
87 % (AUC=0.68, P<0.001, 95% confidence interval=0.589-0.768). The ROC-curve for 
discrimination between the breast tumour group and the healthy control group using ccf mtDNA 
is shown in Fig.3.  
 
 
Discussion 
In our study, according to our knowledge, for the first time we found increased levels of ccf 
nDNA and simultaneously decreased levels of ccf mtDNA in plasma samples from patients with 
breast tumour compared to normal controls. The former shows a probable diagnostic value in 
discriminating between breast cancer and normal controls with a sensitivity of 81 % and 
specificity of 69 % , the latter reveals possible relevance in distinguishing between breast 
tumours (malignant and benign) and normal controls with a sensitivity of  53 % and specificity of  
87 %.  
For ccf nDNA, in our previous work, we observed that in comparison with other potential 
circulating biomarkers involved in malignancy, such as nucleosomes, vascular endothelial growth 
factor (VEGF) and its soluble receptor (sVEGFR1), the ccf DNA showed more sensitivity and 
specificity in discriminating between breast cancer and normal controls [18 , 19]. Recently, Diehl 
et al, explored the possibility of using ccf tumour derived DNA for the management of colorectal 
cancer [20]. Patients with detectable ccf tumour DNA suffered from a relapse, whereas subjects 
without circulating tumour DNA did not experience tumour recurrence. The ccf tumour DNA 
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detection seems to be more reliable for predicting a relapse than the standard biomarker, 
carcinoembryonic antigen (CEA), used for the management of colorectal cancer [21]. It was also 
reported that the levels of ccf DNA could be changed after therapy in breast cancer [22, 23]. The 
observations suggest that determination of ccf DNA in cancer may be an useful tool in the 
management of the condition. 
In this study, we found high levels of ccf plasma DNA related to tumour size. The finding can be 
supported by the investigations in the field of prenatal medicine. Placenta has been regarded as a 
“pseudomalignant”. Placental derived ccf fetal DNA in maternal circulation can be used for risk-
free prenatal diagnosis [24-27]. The concentration of placental derived ccf fetal DNA in maternal 
blood increases with the progress in gestational weeks regarding placental size [28].  Using fetal 
specific DNA sequences, ccf fetal DNA could be detected from the 5th gestational week, and the 
results were reliable by the 8th gestational week with an accuracy of 100% in fetal DNA 
determination [29, 30]. The results imply that using tumour specific genetic alteration as marker, 
tumour derived ccf DNA may be detectable in early stage with small tumour size for early 
diagnosis.   
For mtDNA, either down-or up-regulation in cancer patients has been shown before, and many 
attempts to explain both events have been made. While up-regulation of mtDNA in cancer 
patients was only shown in a few cases [31], many studies including this one found decreased 
mtDNA levels in cancer patients [32-34]. One explanation for lower mtDNA copy numbers in 
cancer patients might be ascribed to mutations or deletions occurring as a consequence of 
exposure of mtDNA to reactive oxygen species (ROS) which are a by-product of respiration and 
oxidative phosphorylation. Especially in the D-Loop region which controls replication and 
transcription of mtDNA, such mutations and deletions may lead to changes in transcription and 
replication rate and finally result in a decrease of mtDNA levels in cancer patients [35]. In this 
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study we found lower levels of mtDNA in the benign group when compared with the cancer 
group. In benign tumors depletion of mtDNA could be a mechanism of tumour cells to escape 
apoptosis and to finally promote cancer progression [36]. On the other hand the relative increase 
of mtDNA levels in the cancer group compared to the benign disease group might be a 
compensatory mechanism of the cells, to respond to the decline in respiratory function [37]. 
In this study we showed that higher levels of ccf nDNA where significantly elevated in breast 
cancer patients in comparison with a benign disease group and a healthy control group while 
lower levels of ccf mtDNA were significantly elevated in the breast tumour group (malignant and 
benign) when compared to the healthy control group. Regarding ccf nDNA levels, our results 
confirmed the findings of other studies which also found altered levels of ccf nDNA in cancer 
patients. For ccf mtDNA the fact that down- as well as up- regulation of ccf mtDNA levels in 
cancer patients has been found in other studies makes it necessary to further investigate mtDNA 
content in different cancer and tumor types, to see if mtDNA content might be cancer type or 
tumor specific. However, both ccf nDNA and mtDNA could be used to discriminate between the 
different study groups. While ccf nDNA could be used for discriminating between patients with 
breast cancer and healthy controls, ccf mtDNA could be used for distinguishing between patients 
with breast tumors (malignant and benign) and healthy controls. Altogether this suggests that ccf 
nDNA might be used as a cancer specific biomarker, whereas ccf mtDNA might be rather used as 
a tumour biomarker.  
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Table 1: Concentrations (GE/mL) of plasma ccf nDNA and ccf mtDNA in the 3 study-groups; 
expressed as median and range. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group  Ccf nDNA (GE/mL) Ccf mtDNA (GE/mL) 
Median 4678 205013 Malignant disease 
group Range 758- 23263 6508 - 6603330 
Median 1359 73977 Benign disease 
group Range 88 - 483209 7887 - 541739  
Median 1298 522115 
Control group 
Range 95 - 30437 3427 - 28327810 
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Fig.2  Boxplot for correlating levels of ccf nDNA between breast cancer patients with a tumour 
size of more than five centimetres (> 5 cm; 4 cases), two to five centimetres (2 cm–5 cm; 25 
cases) and less than 2 centimetres (< 2 cm; 21 cases). Significant difference in the levels of ccf 
nDNA could be found between tumours with a tumour size of two to five centimetres and 
tumours with a tumour size of less than two centimetres. For the group of the tumour size bigger 
than 5 cm, only 4 cases were recruited.  
 
 
 
 
 
 
  129 
 
 
 
 
 
Fig.3  ROC curves using ccf nDNA and mtDNA for discrimination between the study-groups. A) 
ROC curve of ccf nDNA for discrimination between the cancer group and the healthy control 
group (sensitivity = 81 %; specificity = 69 %). B) ROC curve of ccf mtDNA for discrimination 
between the tumour group and the healthy control group (sensitivity = 53 %; specificity = 87 %). 
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Abstract  
Mutations and up-/down-regulations of mitochondrial DNA (mtDNA) have been found in various 
cancers. The mtDNA alterations are suspected to be associated with carcinogenesis. In this study, 
we developed microarray chip based multiplex assay using matrix-assisted laser 
desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) for simultaneously 
detecting 22 mtDNA single nucleotide variants in 6 breast cancer cell lines and in the 102 
cancerous and adjacent breast tissue samples from 51 patients with breast cancer. Totally, 164 
mutations were identified in 66.67% of breast cancer cell lines and in 49.12% patients’ tissue 
samples, in both the cancerous and adjacent parts. Most of the detected mtDNA variants in breast 
cancer samples were distributed in the regions of D-loop, 12S ribosomal RNA, 16S ribosomal 
RNA and tRNA. In our previous study, we found down-regulation of mtDNA in the breast 
cancerous tissues compared to the adjacent tissues. In this study, we investigated the relationship 
between the quantitative and qualitative alterations of mtDNA in breast cancer. No correlation 
was found between the down-regulation and the mutations of mtDNA in breast cancer tissues. 
Also there was no association was found between the mutations and clinic-pathological 
parameters including tumour type, tumour size, lymph node involvement, extent of metastasis, 
stage, histological grading, and ER, PR, and HER-2/neu receptors.  Our study suggests that 
down-regulation and mutations of mtDNA in breast cancer tissues may be resulted by different 
mechanism. Both the qualitative and quantitative alterations of mtDNA in breast cancer may 
serve as biomarkers independent of clinic-pathological parameters for breast cancer on early 
screening, diagnosis, monitoring treatment effects, prognosis, and follow up. MALDI-TOF MS 
based MicroARRAY multiplex assay is a high-throughput, and cost-efficient tool for large scale 
allelotyping of mtDNA informative mutations or single nucleotide mutation in life science.  
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Introduction 
 
 
Mitochondria as cellular power sources play fundamental roles in energy metabolism, generation 
of oxygen species (ROS), aging and initiation of apoptosis. These cellular organelles have their 
own independent genome -mitochondrial DNA (mtDNA), which is a double stranded circular 
DNA of 16.6 kb encoding 13 respiratory chain protein subunits, 22 tRNAs, and 2 rRNAs 
(Anderson et al, 1981). Due to the close proximity to reactive oxygen species (ROS), lack of the 
protective histone proteins and less efficient DNA repair mechanisms, compared to nuclear DNA 
(nDNA), mtDNA is more vulnerable to oxidative injury and has a higher level of mutation rate 
(Croteau et al. 1997; Jackson et al.1998; Zienolddiny et al. 2000), implying their importance in 
pathogenesis of disorders. It was hypothesized that cancer might be caused by the irreversible 
injury to the mitochondrial respiratory machinery (Warburg et al.1924, 1956). Many studies have 
shown that quantitative and qualitative mitochondrial aberrations are seen in various cancers of 
the bladder, breast, head and neck, thyroid, kidney, liver, lung, esophagean, stomach, colorectual, 
overian (Ebner et al. 1991; Horton et al.1996; Mambo et al. 2005; Tseng et al. 2006; Yu et al. 
2007; Simonne et al. 2002; Capuano et al. 1996; Bianchi et al. 1995; Parrella et al. 2001; Zhu et 
al. 2005; Fliss et al. 2000; Kumimoto et al. 2004; Tamura et al. 1999; Polyak et al.1998; Liu et al. 
2001). 
Using temporal temperature gradient gel electrophoresis (TTGE) and 32 pairs of overlapping 
primers, followed by direct DNA sequencing, Tan et al (2002) screened the entire mitochondrial 
genome for somatic mutations of mtDNA in breast cancer. Multi (27 mutations) somatic mtDNA 
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mutations were identified in most of breast cancer tissue samples. Using 9 overlapping primer 
sets, Zhu et al (2005) sequenced the entire mitochondrial genome in breast cancer samples. The 
generated fragments in the study were 1886–2075 base pair in length for the sequencing. Again, 
multi (45 mutations) somatic mutations were discovered in breast cancer tissues in the study. The 
two studies showed the feasibility of screening the entire mitochondrial genome in breast cancer 
tissue; however, the clinical relevance of the finding remains unknown and multiplexed assays 
for simultaneously detecting multiple mutations of mtDNA in a single reaction are currently not 
available.  
In the present study, we used a novel approach combining of MicroARRAY chip based MALDI-
TOF MS and multiplex assay based iPLEX protocol developed by Sequenom (Sequenom, San 
Diego, USA) for simultaneous detection of up to 22 mutations of mtDNA in a single reaction. 
The 22 single nucleotide variants found in breast cancer are distributed on D-loop, 12S ribosomal 
RNA,  16S ribosomal RNA, tRNA, NADH dehydrogenase subunits, ATPase subunit 8, 
Cytochrome C oxidase subunite III, and cytochrome b regions (Zhu et al, 2005). The technique 
meets the requirements of high-throughput assays as a highly automated process and enables 
high-resolution analyses of single nucleotide changes at high multiplex levels. The feasibility of 
22-plex assay for detection of 22 mtDNA variants simultaneously was explored by testing 51 
breast cancerous tissues and 51 corresponding adjacent tissue samples from the same patients, as 
well as by examining 6 of breast cancer cell lines. The relationship between mutations and 
quantitative changes of mtDNA in breast cancer tissues, as well as the correlation between 
mutations of mtDNA and clinic-pathological parameters was analysed. 
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Method and Materials 
 
Tissue samples  
The local ethical committee approved the use of the archived tissues samples. Fifty-one paired 
cancerous and adjacent, formalin-fixed, paraffin-embedded breast tissue samples from patients 
with breast cancer were examined by two experienced pathologists. DNA was extracted from five 
sections of each 10 µm thick paraffin-embedded sample (around 20 mg of tissue) using a High 
Pure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany) according to the 
manufacturer’s protocol and eluted into 150 µl of elution buffer. The eluted DNA was stored at -
20°C until further use.  
 
Cell culture  
MDA-MB-231, MCF-7, and HS578T cells were grown in Dulbecco’s modified Eagle medium 
(DMEM) (4.5g/l glucose L-glutamine); BT549 and T47D cells were grown in RPMI 1640 (L-
glutamine); SKBR3 cells were grown in McCoy’s 5A medium. All media purchased from 
Gibco/Invitrogen (Carlsbad CA, USA) were supplemented 10% FCS and 1% penicillin-
streptomycin. The cells were maintained in a humified incubator at 37°C 5% CO2, and harvested 
at 80% confluency. Before DNA extraction the cells were washed 1xPBS. DNA was extracted 
from 1 X 106 cells by using the High Pure PCR Template Preparation Kit (Roche Diagnostics, 
Mannheim, Germany) and eluted in 100 µl of elution buffer and stored at -20°C until further use. 
 
Quantitative analysis of mtDNA using real-time PCR 
The amounts of nDNA and mtDNA were quantified by multiplex TaqMan real-time PCR for 
both glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene of nDNA and mitochondrial 
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ATPase subunit 8 (MtATP 8) gene of mtDNA starting at locus 8446. The GAPDH and MtATP 8 
primer and probe sequences are shown as follows: GAPDH (forward):5’ CCC CAC ACA CAT 
GCA CTT ACC3’; (reverse): 5’CCT AGT CCC AGG GCT TTG ATT 3’; probe5’ (MGB) TAG 
GAA GGA CAG GCA AC (VIC) 3’. MtATP 8 (forward): 5’ AAT ATT AAA CAC AAA CTA 
CCA CCT ACC 3’; (reverse): 5’ TGG TTC TCA GGG TTT GTT ATA 3’; probe: 5’ (MGB) 
CCT CAC CAA AGC CCA TA (FAM) 3’.The PCR was performed using the ABI PRISM 7000 
Sequence Detection System (Applied Biosystems, ABI). 2.5 µl DNA were used as template for 
the PCR analysis. The real-time PCR was carried out in 25 µl of total reaction volume using a 2 
minute incubation at 50°C, followed by an initial denaturation step at 95°C for 10 minutes and 40 
cycles of one minute at 60°C and 15 seconds at 95°C. 
 
The theory, practice and the amplification efficiency of PCR for both GAPDH and MtATP 8 has 
been demonstrated in our previous study (Xia et al. 2009). According to the comparable 
amplification efficiency of two assays, in our study, the average threshold cycle number (Ct) 
values of the nDNA and mtDNA were obtained from each case for quantitative assessments. The 
content of mtDNA was calculated by using the delta Ct (∆Ct) of average Ct of mtDNA and 
nDNA (∆Ct = CtnDNA-CtmtDNA) in the same well as an exponent of 2 (2∆Ct ). 
 
Detection of mtDNA mutations using microarray chip based MALDI-TOF MS 
The PCR and extension primers used to analyze the mtDNA mutations were designed using 
MassARRAY Assay Design v.3.1 software (Sequenom, San Diego, USA). Based on Cambridge 
Reference Sequence (CRS) of human mitochondrial genome and the publication of Zhu et al 
(2005), we summarized total 45 mutations at 35 nucleotide positions to 37 types of mutant input 
format for the assay design. Due to the compromise of mutation capture amplicon length, extend 
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primer length and the mass range, and to avoid weak extend dimmer potential, false priming 
potential, and extend self-dimmer potential,  22 single nucleotide variants (Table 1) were selected 
by the software randomly available for the analysis at a multiple level in a single reaction. Of 
these 22 somatic mutations, 3 are located  in D-loop, 1 in 12S ribosomal RNA, 1 in 16S 
ribosomal RNA, 2 in tRNA, 11 in NADH dehydrogenase subunits, 1 in ATPase subunit 8, 1 in 
Cytochrome C oxidase subunite III, and 1 in cytochrome b region. Fifteen mutations lead to 
codon changes, and 8 lead to amino acids changes (Table 1, Figure 1). For this study, two primers 
for amplifying each variant (capture primers) and one more primer for extending each mutation 
(extension primer) were designed using the software. The 66 primers for the examination of 22 
single nucleotide variants in total are listed in table 2 (Table 2). A 10-mer tag of 5’-
ACGTTGGATG-3’ to the 5’end of the each primer for PCR amplification was used to avoid 
chaos in mass spectrum and to improve PCR sufficiency according to the manufacture’s protocol.  
The capture PCR reactions for amplifying 22 fragments containing the 22 sequence variants in a 
single well were carried out in 10 µl PCR cocktail mixes comprising 1µl DNA, 1.626mM 
MgCl2, 500uM dNTP mix, 0.5U HotStarTaq DNA polymerase and primer pairs. The 
amplification was performed under the following conditions: incubation at 94°C for 15 minutes, 
followed by 45 cycles of 94°C for 20 seconds, 56°C for 30 seconds, 72°C for 1 minute and final 
extension at 72°C for 5 min. To remove the non-incorporated dNTPs, a shrimp alkaline 
phosphatase (SAP) treatment was performed after the PCR reaction under the following 
conditions: 37°C for 20 minutes, 85°C for 5 minutes and cooling to 4°C. The iPLEX extension 
reaction was performed using the iPLEX gold cocktail mix (Sequeonom, San Diego, USA), 
which contains buffer, termination mix, enzyme and extension primers, under the following 
conditions: 94° C for 30 seconds, followed by 40 cycles of 94°C for 5 seconds, plus 5 sub-cycles 
of 52°C for 5 seconds and 80°C for 5 seconds; one cycle of final extension at 72°C for 5 min, 
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then cooling to 4°C. The iPLEX reaction products were desalted using clean resin to optimise 
mass spectrometric analysis and dispensed onto a 384-element SpectroCHIP bioarray by using a 
nanodispenser (Sequeonom, San Diego, USA) for MALDI-TOF MS analysis. The MassARRAY 
Typer 4.0 software (Sequeonom, San Diego, USA) was used to process and analyze iPLEX 
SpectroCHIP bioarrays. The call rate, extension rate and peak area for all allele-specific analyses 
in any given assay were calculated using the software, Typer 4.0, provided by the manufacturer. 
DNA from a mitochondria negative cell line, which was obtained by sub-culturing that cell line 
in the presence of low concentration of ethidium bromide until the cells were devoid any of 
mitochondria, was used as negative control. The negative control was run at each step and on 
each chip. 
Statistical Analysis 
The data were analyzed using SPSS software (Statistical Software Package for Windows v. 15.0). 
Content of mtDNA is given as the median, the range and the fold difference. The Shapiro-Wilk 
test was used for the analysis of the distribution of data. The Mann–Whitney U test and Kruskal–
Wallis test was applied to compare the mtDNA content between study groups. Pearson chi-square 
test was applied to analyze the association between mtDNA variants and clinicopathological 
parameters. 
 
Results 
Quantitative analysis of mtDNA in 6 cell lines and the tissues samples  
Nuclear DNA and mtDNA were co-extracted from the 107 cultured cells from each cell line. The 
average Ct values for the GAPDH sequence, representing total nDNA, were 26.65, 26.92, 27.01, 
27.40, 24.21, and 17.83 for BT549, HS578T, T47D, SKBR3, MCF-7, and MDA-DB231 cells 
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respectively, while the average Ct values for the MTATP 8 gene sequence, representing total 
mtDNA, were 16.12, 17.26, 15.3, 15.83, 14.38, and 16.3 respectively. The average Ct values of 
mtDNA were less than those of nDNA, and in all cases, represented higher amounts of mtDNA 
than those of nDNA in these cell lines. The ∆CT values between GAPDH gene amplification and 
MTATP 8 gene amplification show 10.53, 9.66, 11.71, 11.57, 9.83 and 1.53 cycles difference 
respectively. The mtDNA content was calculated by the formula of 2∆CT. After normalization to 
GAPDH, mtDNA contents were 1478.58, 809.00, 3350.13, 3040.30, 910.18, and 2.89-fold high 
in BT549, HS578T, T47D, SKBR3, MCF-7, and MDA-DB231 cells, respectively. The content of 
the mtDNA in both cancerous and normal breast cancer tissues from the 51 patients with breast 
cancer has been shown in our previous study (Fan et al, 2009).  
 
22plex MALDI-TOF MS Based MicroARRAY assay for somatic mtDNA mutations  
The advantage of having as high plex level as possible per well is to make the screening of 
somatic mitochondrial DNA mutations more effective. The efficiency of 22-plex assay was 
assessed by call-rate and call-possibility software Typer 4.0 (Sequenom Inc, San Diego, 
Germany) automatically, and revaluated by visual examination of each mass spectrum. Excluding 
the mtDNA negative cells, each of these 22 variants could be identified successfully with a call-
rate range of 89.04% to 100% in 108 samples (102 breast tissue samples and 6 cell lines) (Table 
1). The average of call possibilities is 95.03%.  
Using the 22-plex assay, we analysed the 22 mtDNA variants in 51 cancerous and paired normal 
tissue samples, as well as in 6 cell lines. In total, 164 mutations were found in our examined 
samples. The distribution of the mtDNA variants identified in this study is listed in the table 3. 
MtDNA mutations 709 G>A and 2709 A>G were found in the 4 (MDA-MB 231, MCF-7, BT 549 
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and SKBR 3) out of the 6 cell lines (66.67%), and mtDNA mutations 709 G>A on 12S ribosomal 
RNA (Figure 3) , 2706 A>G on 16S ribosomal RNA (Figure 4), 15924 A>G on tRNA (Figure 5) 
and 16145 A>G on D-loop (Figure 6 and Figure 7) were identified in 25 out of 51 patients 
samples (49.12%). Twenty-two out of 25 patients (88.00%) showed one mutation in their tissue 
samples, while 3 patients had 2. The mutations were distributed in 22 out of 51 cancerous tissues 
(43.14%) and in 24 out of 51 adjacent tissues (47.06%) respectively. The mutation prevalence 
between breast cancer cell lines and breast cancer tissues, as well as between the cancerous 
tissues and adjacent tissues were comparable (p = 0.408 and 1.000 respectively). Most of the 
paired cancerous and adjacent tissues (22/25 = 88 %) showed the identical mutations (Table 3). 
While the cases 807 and 828 showed a completely 16145 A>G mutation in cancerous tissues, a 
mixture of a wild-type form G and a mutant form A was found in the adjacent tissue. For the 
cases 824, 829 and 846, we found mutations 709 G>A or 16145 A>G in adjacent tissues, but not in 
cancerous tissues. In all of the samples, a 311-315 insertion C was found, in which 49 out of 51 
cases showed a homoplasmic form (Figure 8) and two cases (822 and 841) revealed a 
heteroplasmic alteration (Figure 9). We assume that the 311-315 insertion C might be a 
polymorphism in the study cohort and is not listed in the table 3.  
In the cancerous tissues, we found 164 mutations at 5 nucleotide positions in all 6 cell lines and 
51 paired tissue samples. Ten out of these mutations were only present in 6 cell lines and 154 out 
of those were found in tissue samples. Of 56.86% (29/51) cancerous tissue samples, 50.98 % 
(26/51) normal tissue samples and 33.33% (2/6) cell lines, each had one mutation detected. In 
41.18 % (21/51) cancerous samples, 47.06 (24/51) normal samples and 66.67% (4/6) cell lines, 2 
mutations were identified in each sample, while in one paired samples 3 sequence variants were 
found in both normal and cancerous samples (Table 3). The sequence variants at np 311-315 
were found in all the samples. One C insertion at np 311-315 (Figure 3) was the most frequent 
  148 
sequence variant identified in 49 pairs of tissue samples and 6 cell lines. 709A and 2706 A were 
also identified in both tissue samples and cell lines (Figure 5, 6). 15924 G, 16145 A and 16145 
AG were found only in tissue samples (Figure 7, 8, 9). In paired tissue samples, 8 (5.2%) of the 
sequence variant were heteroplasmic, and 146 (94.8%) were homoplasmic. 4 heteroplasmic C 
ins/- at np311-315 (Figure 4) were found both in 2 paired cancerous and normal samples, while 
the other 4 heteroplasmic AG at np 16145 (Figure 8) were found in 4 different normal tissue 
samples. 12 sequence variants found in either cancerous or normal tissue samples were different 
from the paired corresponding samples. All the detected sequence variants were distributed at 5 
np in a hotspot region around the D-loop; two were in D-loop, one in 12S RNA, one in 16S RNA, 
and one in tRNA- threonine. 
Due to the extremely high frequency of sequence variant at np 311-315, a single-plex MALDI-
TOF MS based MassARRAY assay was performed to confirm the detection, and the coherent 
results were identified by single-plex assay in comparison with the results by 22 plex assay. The 
sequence variant at np 311-315 present in all samples was regarded as a physiological variation 
and excluded from the further analysis in this study.  
In this study we investigated the relationship between reduced mtDNA content and mtDNA 
mutations in breast cancer.  For the 6 breast cancer cell lines, it doesn’t seem the mtDNA content 
associates with mtDNA mutations conditions. 
 
For the analysis of the 51 paired tissue samples, we divided the cases into different subgroups 
according to sequence variants on mtDNA and sample types. In both of cancerous and normal 
tissue samples the samples containing mtDNA sequence variants showed significant reduced 
mtDNA contents (P=0.039) compared to the samples without detectable mtDNA variants. 
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However, the quantitative alteration of mtDNA in the tissues were not found having any 
association with any single certain variation at nucleotide positions of 709, 2706, 15924, and 
16145 mutations respectively (Table 4). Likewise, no significant difference was found in the 
comparison of mtDNA content between the groups with and without sequence variants within 
either normal or cancerous tissue groups, therefore most likely in this Iran cohort the difference 
of mtDNA content between with and without variant groups was caused only by the different 
tissue types (Table 4). 
 
Furthermore we analyzed the relationship between somatic mtDNA mutation status and the 
traditional clinicopathological factors in breast cancer patients. In this study we did not find 
somatic mtDNA mutations was associated with age, tumour type, tumour size, lymph node 
involvement, extent of metastasis, stage, histological grading, and ER, PR, and HER-2/neu 
receptors (Table 5). As well in breast cancer patients with mtDNA variants we did not find any 
association between tissue types and clinicopathological parameters (Table 6). 
 
Discussions 
 
Many mtDNA mutations have been observed in many cancers; however, there were no common 
mutations could be found in a certain cancer type for subsequent investigations, suggesting that a 
high-throughput assay for individually detecting multiple mutations simultaneously is requested.  
In our study, we developed a MALDI-TOF MS based MicroARRAY multiplex assay to detect 22 
mtDNA sequence variants in a single reaction. We found mtDNA sequence variants in all 6 cell 
lines, cancerous and normal tissue samples. Except the sequence variant at 311-315 np, the 
frequency of a sequence variant at each nucleotide position was identified in tissue samples at a 
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variant range from 7.41% to 14.71 %. In the study by Zhu et al (Zhu et al. 2005) the parentages 
of mutation at each np were ranged from 3.33% to 10 % of 15 paired breast cancerous tissue 
samples. In the other two studies on breast cancer this rate is from 2.63 to 10.53% in 19 paired 
tissue samples (Tan et al. 2002) and from 0.83% to 10% in 60 paired tissue samples (Yu et al. 
2007) respectively. 
 
In this study the sequence variants were detected at 5 np in D-loop and the neighbourhood tRNA 
threonine, 12S and16S RNA genes, none in any coding region. The similar regions have been 
reported as hot spots for high mutation frequency of the mitochondrial genome (Fliss et al. 2000; 
Liu et al. 2001; Tan et al. 2002; and Tseng et al. 2006). It has also been reported that somatic 
mitochondrial mutations in the D-loop, the replication control region, are associated with a 
reduction of mtDNA content (Lee et al. 2004; Tseng et al. 2005).   
In breast cancer, besides the alterations in the nucleotide sequence, the alterations in mtDNA 
content (Mambo et al 2005; Tseng et al 2006; Yu et al. 2007) had also been reported. It has been 
suspected that both mtDNA content alteration and mtDNA mutations were involved in the 
development and progression of malignant neoplasm (Shay et al. 1987). In our previous study we 
found mtDNA content decreased in cancerous breast tissue samples compared with the 
corresponding normal tissue samples (Fan et al. 2009). In this study we identify the mtDNA 
sequence variants happened at np 311-315 identified in all the samples, which is most likely a 
physiological polymorphism. Even firstly it has been reported a simple repeat of five cytosine 
residues at np 311−315 as rare polymorphic alleles in CRS, whereas it was also stated in the 
reanalysis and revision by the investigators there are six residues at the same np in most other 
human mtDNAs (Richard et al. 1999). Similarly as indicated in Global human mtDNA 
phylogenetic tree - Build 3 (1 Mar 2009) analysis, the highly recurrent sequence variation 315. 
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1C were not regarded as phylogenetic reconstruction subsequently excluding from mtDNA 
phylogenetic tree (van Oven et al. 2009). Therefore we do exclude 1C insertion at 315 from the 
further association analysis. 
The method we used for this study has been shown a good sensitivity to detect as a low amount 
as 5% variant mtDNA submerged in a wild type background (Fan et al. 2008), and compared 
with sequencing an accuracy of more than 99.86% concordance could be achieved (Garritsen et 
al. 2008). However, it could be undetectable if a mutation potential was lower than 5%, when 
some rare variants alleles were submerged among vast predominance of normal sequences. In 
addition, the mutations outside of this combination of 22 np can not be detected by this assay, 
which need to be further investigated. 
To the best of our knowledge, this is the first report of highest multiplex assays for simultaneous 
detecting mutations of mtDNA. Compared to the conventional methods, the MALDI-TOF MS 
based MicroARRAY multiplex assay is a high-throughput and cost-efficient method, which 
could be a sufficient tool for large scale somatic mtDNA mutation analysis, and might have far-
reaching potential on routine clinical application. 
. 
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Nucleotide 
position (np) 
Reference 
sequence 
Nucleotide 
change Gene 
Codon 
change 
Amino acid 
change 
Success of 
Assay (%) 
207 G G>A D-Loop NCL  95.18 
311-315 CCCCC C ins D-Loop NCL  100 
709 G G>A 12S NCL  99.12 
2706 A A>G 16S NCL  97.81 
3849 G G>A ND1 TTG-TTA NO 99.12 
4323 T T> C tRNA-I NCL  97.37 
4499 C C>T ND2 TAC-TAT NO 99.12 
4665 G G>A ND2 GCA-ACA A60T 99.12 
5240 A A>T ND2 CTA-CTT NO 98.24 
8498 A A>G ATP8 AAA-GAA K45E 92.98 
9885 T T>A COXIII TTT-ATT F227I 100 
11768 A A>G ND4 ACT-GCT T337A 97.37 
12642 A A>G ND5 GAG-GAA NO 98.68 
12852 C C>T ND5 ATC-ATT NO 96.93 
13263 A G>A ND5 CAG-CAA NO 89.04 
13398 A A>T ND5 CAA-CAT Q354H 96.93 
13674 T T>G ND5 AAT-AAG N446K 96.93 
15700 C C>T ND5 CGC-CGT NO 99.12 
15783 C C>T CYTB CTT-CCT L346P 99.12 
15824 A A>G CYTB ACA-GCA T360A 99.56 
15924 A A>G tRNA-T NCL  97.37 
16145 G G>A D-Loop NCL  97.81 
 
Table 1. mtDNA sequence variants in breast cancer were selected for 22plex MS-ARRAY assay.  
NCL, no coding locus; 12S, 12S ribosomal RNA; 16S, 16S ribosomal RNA; ND 1, 2, 4, 5, 
NADH dehydrogenase subunit 1, 2, 4, 5; tRNA-I, tRNA isoleucine; ATP8, ATP synthase subunit 
8; COXIII, cytochrome c oxidase subunit III; tRNA-T, tRNA threonine; ins, insertion. 
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Mutation Mutation capture Primer Extension primer 
Mt311-315 ACGTTGGATGAAATTTCCACCAAACCCCCC ACGTTGGATGGCTGGTGTTAGGGTTCTTTG CAAACCCCCCCTCCCCC 
mt4499 ACGTTGGATGTGTTGGTTATACCCTTCCCG ACGTTGGATGTGATGAGTGTGCCTGCAAAG GCCCAACCCGTCATCTA 
mt4665 ACGTTGGATGCATCAAGTATTTCCTCACGC ACGTTGGATGATGGTTCATTGTCCGGAGAG TCCTCACGCAAGCAACC 
mt709 ACGTTGGATGAGGTTTGGTCCTAGCCTTTC ACGTTGGATGTCGTGGTGATTTAGAGGGTG GGGTGAACTCACTGGAA 
mt15783 ACGTTGGATGGCAGACCTCCTCATTCTAAC ACGTTGGATGCGGATGCTACTTGTCCAATG GACAACCAGTAAGCTACC 
mt15700 ACGTTGGATGTCCCCATCCTCCATATATCC ACGTTGGATGGCGGCTAGGAGTCAATAAAG gAGTGATTGGCTTAGTGG 
mt3849 ACGTTGGATGACACCTCTGATTACTCCTGC ACGTTGGATGTCGGTTGGTCTCTGCTAGTG TCCTGCCATCATGACCCTT 
mt13398 ACGTTGGATGCTATTTATGTGCTCCGGGTC ACGTTGGATGGGTTGAAGTGAGAGGTATGG ACAACCTTAACAATGAACA 
mt9885 ACGTTGGATGTATCTGCTTCATCCGCCAAC ACGTTGGATGAAAATGCCAGTATCAGGCGG TCCGCCAACTAATATTTCAC 
mt5240 ACGTTGGATGCTTAATTCCATCCACCCTCC ACGTTGGATGCTTCGATAATGGCCCATTTG gATTTGGGCAAAAAGCCGGT 
mt2706 ACGTTGGATGAGGGTTCAGCTGTCTCTTAC ACGTTGGATGCATAGGGTCTTCTCGTCTTG gttaTTCTCGTCTTGCTGTGT 
mt11768 ACGTTGGATGCGGGCTTACATCCTCATTAC ACGTTGGATGTGAGAGAGGATTATGATGCG gggcACTCAAACTACGAACGC 
mt4323 ACGTTGGATGCCCTCAAACCTAAGAAATATG ACGTTGGATGGGTTCGATTCTCATAGTCCT ccccATAGGAGCTTAAACCCCC 
mt12642 ACGTTGGATGCATCCCTGTAGCATTGTTCG ACGTTGGATGGATTAATGTTTGGGTCTGAG gaGTTACATGGTCCATCATAGA 
mt15824 ACGTTGGATGCATTGGACAAGTAGCATCCG ACGTTGGATGGGGAGATAGTTGGTATTAGG cctcAGCATCCGTACTATACTTC 
mt12852 ACGTTGGATGATCAGTTGATGATACGCCCG ACGTTGGATGGAAACCGATATCGCCGATAC ttctCAGCAGCCATTCAAGCAAT 
mt15924 ACGTTGGATGAAATGGGCCTGTCCTTGTAG ACGTTGGATGTTTCTCTGATTTGTCCTTGG acACTAATACACCAGTCTTGTAA 
mt16145 ACGTTGGATGGCCAGCCACCATGAATATTG ACGTTGGATGGGGTTTTGATGTGGATTGGG TATTGTACGGTACCATAAATACTT 
mt13674 ACGTTGGATGGCTTCCCCACCCTTACTAAC ACGTTGGATGAATCCTGCGAATAGGCTTCC cccCCCTTACTAACATTAACGAAAA 
mt13263 ACGTTGGATGATCGTAGCCTTCTCCACTTC ACGTTGGATGAGGAATGCTAGGTGTGGTTG ttATTGTAACTATTATGAGTCCTAG 
mt8498 ACGTTGGATGCACAAACTACCACCTACCTC ACGTTGGATGCGTTCATTTTGGTTCTCAGG GGTTCTCAGGGTTTGTTATAATTTT 
mt207 ACGTTGGATGTTACAGGCGAACATACTTAC ACGTTGGATGAAGTGGCTGTGCAGACATTC tacatGCGAACATACTTACTAAAGTGT 
  
Table 2. Sequences of 22plex mtDNA variants capture and extension primers. 
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Sample 
counting 
Sample ID characteristics  Nucleotide position 
(np) Adjacent Cancer (Cell line) 
1 MDA-MB 231  709  A 
2 MCF-7  2706  A 
3 BT 549  2706  A 
4 SKBR 3  2706  A 
1 802 IDC 709 A A 
2 803  2706 A A 
3 804  16145 A A 
4 807  16145 AG A 
5 812  16145 AG  
 812  709  A 
6 815  2706 A A 
7 817  16145 A A 
8 819  709 A A 
9 821  16145 A A 
10 822  311-315 C ins/- C ins/- 
11 823  709 A A 
 823  2706 A A 
12 824  709 A  
13 825  16145 A A 
14 827  15924 G G 
15 828  16145 AG A 
16 829  709 A  
17 830  15924  G 
18 838  15924 G G 
19 840  709 A A 
20 841  311-315 C ins/- C ins/- 
21 843  2706 A A 
22 844  16145 AG  
 844  15924  G 
23 846  16145 A  
24 851  15924 G G 
25 853  709 A A 
 
 
Table 3.  mtDNA sequence variants were found in tissue samples. *Besides 822n/p and 841n/p 
paired samples only have one of C ins/- heteroplasmic mutations, each of the rest samples and 
cell lines have one mutation of C ins.  (IDC = invasive ductal carcinoma) 
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Group 
 
Case (percentage) mtDNA content P value 
709- 
 
89 (87.25) 15.35 (1.17-69272.73) 0.098* 
709+ 
 
13 (12.75) 56.69 (1.56-2730.60) 
 
2706- 
 
94 (92.16) 15.19 (1.17-69272.73) 0.700* 
2706+ 
 
8 (7.84) 39.98 (1.49-2730.60) 
 
15924- 
 
94 (92.16) 15.19 (1.17-69272.73) 0.429* 
15924+ 
 
8 (7.84) 63.60 (2.17-13587.57) 
 
16145- 
 
86 (84.31) 21.05 (1.17-69272.73) 0.800* 
16145+ 
 
16 (14.71) 13.27 (1.35-749.61) 
 
Var – 
 
60 (58.82) 9.73 (1.17-69272.73) 0.039* 
Var+ 
 
42 (41.18) 37.42 (1.35-13587.57) 
 
1N & Var – 
 
28 (27.45) 60.38 (3.05-9877.98) 1vs2: 0.130*; 3vs4: 0.070* 
2N & Var+ 
 
23 (22.55) 216.02 (1.35-3888.51) 1vs3: 0.000*; 2vs4: 0.013* 
3C & Var – 
 
32 (31.37) 3.89 (1.17-69272.73) 0.421** 
4C & Var+ 
 
19 (18.63) 15.03 (1.49-13587.57) 
 
 
 
Table 4. Sample profile of mtDNA content and variant groups (excluding 311-315). N: normal; C: 
cancerous; Var: Sequence Variant; “-”: without; “+”: with. * Mann-Whitney U test in normal 
tissue; ** Chi-square test was applied to analyze the association between tissue type and 
mutation. 
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mtDNA content 
Variables 
Group 
(percentage of 
mutation:%) 
Without variant 
Median (range) 
cases 
With variant 
Median (range) 
cases 
P value 
<50       (35.48) 89.33 (3.05-9877.98) 
 N=20  
216.02 (1.35-2460.95)  
N=11  
Age 
≥50       (26.32) 51.58 (4.21-3888.51)  
N=14 
346.09 (3.42-2730.60)  
                   N=5 
0.500 
 
Ductal   (31.71) 45.35 (3.05-9877.98)  
N=28 
346.09 (1.35-2730.60)  
N=13 
Histological type 
Lobular (40.00) 352.46 (15.35-823.14)  
N=6 
201.39 (7.31-584.07)  
N=4 
0.618 
 
T1         (43.48) 106.15 (4.21-982.29) 
 N=13 
201.39 (1.35-749.61)  
N=10 
T2         (20.00) 34.94 (3.05-3888.51)  
N=12 
554.48 (30.91-2730.60)  
N=3 
Primary tumor 
T3         (30.00) 37.67 (5.31-2304.12)  
N=6 
346.09 (22.86-2460.95)  
N=3 
0.328 
Negative(22.22) 72.50 (3.50-9877.98)  
N=7 
108.68 (1.35-216.02)  
N=2 
Lymph node involment 
Positive (36.59) 60.38 (4.21-3888.51)  
N=26 
346.09 (3.42-2730.60)  
N=15 
0.410a, 
 
M0        (30.00) 89.33 (3.05-9877.98)  
N=28 
201.39 (1.35-2730.60) 
N=12 
Metastasis 
M1        (50.00) 49.35 (6.43-560.28)  
N=5 
420.22 (3.42-584.07)  
N=5 
0.410a,  
 
I            (40.00) 9.48 (3.05-106.15) 
 N=3 
108.68 (1.35-216.02)  
N=2 
II           (25.93) 69.73 (4.21-3888.51)  
N=20 
186.75 (7.31-2730.60)  
N=7 
III          (50.00)  823.14 (25.99-2304.12)  
N=3 
346.09 (22.86-2460.95)  
N=3 
Stage 
IV         (44.44) 49.35 (6.43-560.28) 
 N=5 
487.35 (7.31-584.07)  
N=4 
0.232a,  
 
G1        (37.50) 9.48 (3.05-2304.12)  
N=5 
689.78 (30.91-2460.95) 
N=3 
G2        (31.58) 72.50 (5.31-982.29)  
N=13 
450.29 (22.86-749.61)  
N=6 
Histological grading 
G3        (30.00) 33.67 (4.21-3888.51)  
N=10 
149.09 (7.31-2730.60)  
N=5 
0.957a,  
 
1            (0.00) 9.48 (5.13-106.15)  
N=3 
 
N=0 
2           (35.71) 41.36 (3.05-2304.12)  
N=9 
346.09 (30.91-689.78)  
N=5 
Nuclear grading 
3           (50.00) 70.21(4.21-861.08)  
N=8 
85.97 (3.42-2460.95)  
N=8 
0.249a,  
 
Negative(38.89) 49.35(6.70-560.28)  
N=11 
186.75 (3.42-749.61)  
N=7 
ER 
Positive (35.71) 823.14 (6.43-3888.51)  
N=9 
689.78 (7.31-2730.60) 
 N=5 
0.854a,  
 
Negative(42.86) 36.67 (6.43-982.29)  
N=8 
78.20 (3.42-554.48)  
N=6 
PR 
Positive (30.00) 160.58 (9.48-3888.51)  
N=12 
719.70 (30.91-2730.60) 
N=6 
0.581a,  
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Negative(30.00) 210.67 (6.43-3888.51)  
N=10 
584.07 (30.91-2730.60) 
N=5 
Her2 
Positive (41.18) 51.58 (6.70-982.29) 
 N= 10 
149.09 (3.42-2460.95)  
N=7 
0.647a,  
 
Negative(57.89) 89.81(6.43-3888.51) 
 N=18 
186.75 (3.42-2460.95) 
N=11 
P53 
Positive (30.00) 1205.14 (106.15-2304.12)  
N=2 
2730.60 (2730.6-2730.60)  
N=1 
0.876a,  
 
Negative(40.00) 89.81 (6.70-3888.51) 
 N=12 
370.62 (7.31-2460.95)  
N=8 
PS2 
Positive (27.27) 195.10 (6.43-2304.12)  
N=8 
689.78 (7.31-2730.60)  
N=3 
0.479a,  
 
Negative(35.48) 115.98 (6.43-3888.51)  
N=20 
554.48 (7.31-2730.60) 
N=11 
Ki62 
Positive 
 
N=0 N=0 
 
 
 
Table 5. Pearson chi-square test was used to analyze association between mtDNA variants and 
clinicopathological parameters in 51 breast cancer patients.  
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Normal Cancerous Variable Group 
Mut + Mut + 
P-value 
< 50 14 (56.00) 11 (44.00) Age 
≥ 50 8 (61.54) 5 (38.46) 0.743 
Ductal 18 (58.06) 13 (41.94) Histological type 
Lobular 5 (55.56) 4 (44.44) 0.893 
T1 10 (50.00) 10 (50.00) 
T2 6 (60.00) 3 (30.00) 
Primary tumor 
T3 5 (62.50) 3 (37.50) 
0.657 
Negative 2 (13.33) 13 (86.67) Lymph node 
involment Positive 20 (83.33) 4 (16.67) 1.796 
M0 17 (58.62) 12 (41.38) Metastasis 
M1 5 (50.00) 5 (50.00) 0.635 
I 2 (50.00) 2 (50.00) 
II 10 (58.82) 7 (41.18) 
III 5 (62.50) 3 (37.50) 
Stage 
IV 4 (50.00) 4 (50.00) 
0.948 
G1 4 (57.14) 3 (42.86) 
G2 8 (57.14) 6 (42.86) 
Histological type 
G3 7 (58.33) 5 (41.67) 
0.998 
1 0 0 
2 9 (64.29) 5 (35.71) 
Nuclear grading 
3 7 (46.67) 8 (53.33) 
0.340* 
Negative 9 (56.25) 7 (43.75) ER 
Positive 8 (61.54) 5 (38.46) 0.774 
Negative 7 (53.85) 6 (46.15) PR 
Positive 10 (62.50) 6 (37.50) 0.638 
Negative 9 (64.29) 5 (35.71) Her2 
Positive 8 (53.33) 7 (46.67) 0.550 
Negative 15 (57.69) 11 (42.31) P53 
Positive 2 (66.67) 1 (33.33) 0.765 
Negative 11 (57.89) 8 (42.11) PS2 
Positive 5 (62.50) 3 (37.50) 0.824 
Negative 16 (59.26) 11 (41.74) Ki62 
Positive 0 0  
 
 
 
Table 6. Pearson chi-square test was applied to the analyze association between tissue types and 
clinicopathological parameters in breast cancer patients with mtDNA variants. *P-value from 2x2 
contingency table. 
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Figure1. mtDNA encodes 37 genes including 22 tRNA (were labelled in yellow) and 2 rRNA 
(were labelled in red) genes and 13 polypeptide genes (ND1, 2, 3, 4L, 4, 5, and 6 were labelled in 
green, COX1, 2, and 3 were labelled in blue, ATP 6 and 8 were labelled in light blue, and D-loop 
were labelled in black) being written in bigger bold italic letter. 22 mitochondrial variants were 
labelled  black bar and nucleotide positions were written in smaller regular numbers. 
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Figure 2.  Mass spectra of mtDNA 22plex assay. Mass peaks of unextended extension primers 
and different alleles were labelled in different colours. 
 
 
Figure 3. 709A was found in 14 tissue samples and 1 cell line. 
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Figure 4. 2706 A was found in 8 tissue samples and 3 cell lines. 
 
 
 
 
 
Figure 5. 15924 G was found in 8 tissue samples. 
  166 
 
 
 
Figure 6. 16145 A was found in 11 tissue samples. 
 
 
 
 
 
 
Figure 7. 16145 AG was found in 4 tissue samples. 
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. 
Figure 8. C insertion at np 311-315 was found in 49 pairs of tissue samples and 6 cell lines. 
 
 
 
 
 
Figure 9.  C ins/- at np 311-315 was found in 2 pairs of tissue samples. 
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Figure 10. mtDNA in variant positive and variant negative normal and cancerous tissues. N: 
normal; C: cancer; Var: Variant; “-”: without; “+”: with. 
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